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Protein silencing is an important aspect of both therapeutic 
targeting of aberrant protein activity and scientific investigation of native 
protein function. Many different techniques for silencing proteins at the 
DNA or RNA level exist, but new adaptable technologies are needed to 
effectively silence proteins at the post-translational level, and particularly 
with post-translational modification resolution. One such technology, 
developed by the DeLisa laboratory and termed ubiquibodies, hijacks 
natural cellular mechanisms to silence proteins post-translationally. A 
synthetic enzyme—the ubiquibody—functions by connecting two 
independent polypeptide domains, a target recognition domain and a 
catalytic domain via a flexible linker. This project has focused on mapping 
the tolerances of the ubiquibody technology. Expanding the range of 
silenced targets has been a key goal, as well as investigation into each of 
the three ubiquibody domains: target recognition, catalytic, and the 
linker between. 
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CHAPTER 1 
INTRODUCTION: NEXT GENERATION UBIQUIBODIES 
 
Introduction 
Silencing a protein is a powerful action. Depending on the protein, 
a disease may be cured, a discovery may be made, or an entirely new 
biological system may be created. When defining ‘protein silencing’, the 
natural function of a protein must be abolished, either by removal or 
inhibition of the polypeptide. When a protein is silenced, the function it 
performs within a biologic system is effectively lost, resulting in 
phenotypic changes. 
Following the central dogma, proteins are synthesized by the 
transcription of DNA into RNA, and subsequent translation of RNA into 
protein. Thus, if a protein need be silenced, there are three canonical 
stages at which that protein’s existence can be disrupted: DNA, RNA, or 
protein (Figure 1.1). Deletion of specific genes from the genome can lead 
to the complete loss of all encoded proteins from a system. Alternatively, 
messenger RNA (mRNA) can be destroyed before being translated from 
nucleic to amino acid, preventing the synthesis of any new protein. The 
third canonical stage at which proteins may be silenced is the protein 
level, either by removal of all copies of the peptide or by effective inhibition 
of every copy’s function.  
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Figure 1.1: Silencing at different levels of protein synthesis.  
The ratio of gene:mRNA transcript:protein product is not always 1:1:1. Alternative 
splicing can lead to multiple mRNA transcripts derived from the same gene. Post-
translational modification can further diversify protein populations. 
 
However, the nascent polypeptides released by the ribosome are 
rarely the final form of any protein. A fourth level of protein synthesis, 
beyond the central dogma, occurs with post-translational modification of 
the protein [1]. The vast majority of protein diversity comes from post-
translational modifications (PTMs) (Figure 1.2a), and the types of PTM 
vary greatly, ranging from simple phosphorylation (the addition of a small 
phosphate group, -PO4) to glycosylation (the addition of any number of 
complex glycan structures) (Figure 1.2b). The number of unique proteins 
is nearly three orders of magnitude greater than the number of unique 
genes.  
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Figure 1.2: Prost translational modification of proteins.  
(a) The complexity of proteins is increased by both post-transcriptional modification 
and post-translational modification. Adapted from ThermoFisher Scientific [2]. (b) Post 
translational modifications vary greatly in structure and complexity, ranging from 
addition of small chemical groups to cross-linkages of the polypeptide itself to 
conjugation of large macromolecular compounds. Adapted from Rockland [3].  
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Protein Silencing Levels 
Current technologies developed to silence proteins span the first 
three stages of protein synthesis.  
The ultimate silencing technology is the gene knockout; if the 
blueprint for a protein is deleted, that protein will never exist inside cells. 
Gene knockouts can be accomplished in many ways, depending on the 
cell type or organism being manipulated. Perhaps the most striking 
example of this type of protein silencing is the yeast knockout (YKO) 
collection, in which each gene in the S. cerevisiae genome was 
methodically knocked out one by one [4]. Notably, from this screen came 
a large percentage of genes, 18.7%, that were classified as essential for 
growth, due to loss of viability of the organism upon their deletion [5]. 
These essential genes are critical to biological function and often are the 
most in need of silencing, either for investigation or therapeutic 
treatment. Also, while quite powerful, gene knockouts were, for many 
years, inaccessible in model organisms less amenable to gene 
manipulation compared to yeast.  
In answer to these difficulties, a revolutionary mechanism of gene 
knockout, clustered regularly interspaced short palindromic repeats, 
(CRISPr) which emerged near the start of this project, has blown open the 
door for protein silencing in many organisms that could previously not 
be studied at the DNA level [6]. CRISPr functions by repurposing a 
naturally occurring bacterial system, and has been streamlined to require 
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a single guide RNA (gRNA) and a single endonuclease, Cas9. When 
combined, these two elements make a powerful genome editing tool that 
can delete from, modify, or insert into a genome [7].  However, many of 
the same limitations that apply to traditional knockout methods also 
apply to CRISPr; essential genes cannot be completely silenced without 
catastrophic failure of the system’s viability, and thus can only be 
targeted obliquely. Therefore, it is necessary to supplement DNA-level 
protein silence with other technologies that can parse essential gene 
function from organism survival. 
The discovery of RNA-level silencing was quite by accident [8], 
though it has proved invaluable when moving to less genetically tractable 
systems, such as polyploid and eukaryotic systems. RNA interference 
(RNAi) works by hijacking a cell’s natural defense mechanism against 
viruses. Introduction of double stranded RNA, complimentary to an 
mRNA of interest, can efficiently and effectively lead to the destruction of 
that mRNA, preventing its translation [9]. Further advancements in RNAi 
gave a huge boost to the temporal control of protein silencing [10]. Unlike 
with DNA-level silencing, when a biological system is manipulated at the 
RNA level, even if the loss of a protein causes the loss of system viability, 
the ways in which it shuts down become observable. This allows 
observation of phenotypes more specific than ‘non-viable’ to be connected 
to otherwise elusive essential genes.  
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Where RNAi struggles is with highly stable proteins that are turned 
over too slowly to observe measurable changes in phenotype caused by 
the inhibition of new protein synthesis. Proteins with half-lives on the 
order of hours or days are difficult to silence in a meaningful way with 
RNAi, to say nothing of proteins like collagen, which can survive for years 
[11]. Thus it is important to further complement DNA- and RNA-level 
silencing techniques with technologies that are adaptable to stable, 
essential proteins.  
Protein-level silencing offers spatial and temporal control that is 
often difficult at earlier stages of protein synthesis. Most therapeutics 
function at the protein-level, due to the dangers of tampering with the 
genetic code of fully-developed, multicellular organisms. And although 
most protein-level approaches are susceptible to partial silencing (where 
intermediate phenotypes are observed due to incomplete inhibition of 
protein function) this is the only place where protein silencing can be 
achieved at post-PTM resolution. The purpose of this project has been to 
further develop a protein-level silencing technology, called ubiquibodies, 
that has the potential to silence native eukaryotic proteins by hijacking 
existing cellular mechanisms.  
 
The Ubiquitin Proteasome Pathway 
Eukaryotic cells naturally silence proteins effectively and 
efficiently; the involved mechanisms likely evolved due to the need for 
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rapid protein turnover to move through different stages of the cell’s life 
cycle and to respond quickly to environmental changes. The two primary 
mechanisms by which cells silence proteins are the Ubiquitin Proteasome 
Pathway (UPP) and the lysosomal degradation via sorting and autophagy 
[12]. The targeted silencing potential of the lysosome has remained 
largely unexplored, though future generations of ubiquibodies and other 
technologies may soon tap into it (see Chapter 5).  
The UPP utilizes a cascade of three enzymes: E1, E2, and E3, to 
covalently tag substrate proteins with a small peptide modifier, ubiquitin 
(Figure 1.3) [13]. Ubiquitination, the act of tagging with ubiquitin, occurs 
on surface lysine residues of the target; additionally, ubiquitin itself has 
seven lysine residues that can be ubiquitinated. Poly-ubiquitin chains of 
specific lysine linkages (K11 and K48) target marked substrates to the 
proteasome, where the ubiquitin tag is cleaved and the target protein 
destroyed by proteolysis. The proteasome is largely unspecific, allowing 
for a wide diversity of substrates to be recycled into their respective amino 
acids. Because the proteasome is non-specific for any particular 
polypeptide sequence, it falls to the E3s to determine which proteins 
should be tagged for degradation. In the human genome, there are 
approximately 700 E3s, many of which have additional chaperones, 
which adapt the UPP to an enormous range of substrates. This complex 
network of E3s allows for both tight and dynamic regulation of proteome 
through targeted protein degradation [14].  
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Ubiquibodies are synthetic E3 ubiquitin ligases, engineered to 
hijack the UPP. The ubiquibody recognizes a specific non-native target of 
interest and ubiquitinates it, so that it may meet an untimely end at the 
many peptidases of the proteasome.  
 
 
Figure 1.3: Hijacking the ubiquitin proteasome pathway.  
Ubiquitin is activated in an ATP-dependent manner by the E1 activating enzyme. It is 
then transferred to an E2 conjugating enzyme, and then to a substrate protein (S) by 
an E3 activating enzyme. Poly-ubiquitination of a single substrate leads to recognition 
and subsequent degradation by the proteasome. Ubiquibodies (E3*) utilize existing E1 
and E2 machinery to tag target proteins (T) for degradation.   
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Ubiquibody Design 
An E3 ubiquitin ligase minimally consists of a target binding 
domain and a catalytic domain. The initial design of ubiquibodies used 
an N-terminal target recognition domain fused to a C-terminal catalytic 
domain via a short flexible linker (Figure 1.4). In previous work, 
ubiquibodies specific for two different bacterial targets were characterized 
based on their ability to bind their respective target, catalyze the 
formation of poly-ubiquitin chains, and facilitate the degradation of those 
targets in living cells [15]. The two targets, β-galactosidase (β-gal) and 
maltose binding protein (MBP) differ greatly in size and structure, but 
were effectively silenced by ubiquibodies. 
 
 
Figure 1.4: Modular design of ubiquibodies.  
Ubiquibodies consist of three independent domains: target recognition, linker, and 
catalytic domain.  
 
This project has focused on mapping the tolerances of the 
ubiquibody technology. Expanding the range of targets has been a key 
goal, as well as investigation into each of the three ubiquibody domains: 
target recognition, catalytic, and the linker between.   
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CHAPTER 2 
THE DESIGNER BINDING PROTEIN 
 
Introduction 
The first requirement of a ubiquibody is target specificity.  
Historically, and most famously, the antibody is the go-to protein 
for specific target recognition [16-18]. The primary function of an 
antibody is to bind to distinct polypeptide sequences or folds with high 
specificity. Ubiquibodies require a similar capability. However, unlike 
antibodies, ubiquibodies localize intracellularly, and, while cytoplasmic 
usage of antibodies has been shown [19], the cell’s internal reducing 
environment is not ideal for these proteins. Antibodies are large, multi-
chain proteins that require disulfide bonds and glycosylation for optimal 
function [20]. Additionally, the secondary functionality of immunogenic 
response activation that antibodies have is unnecessary to ubiquibody 
design. Therefore, the ubiquibody’s target specificity must mimic that of 
an antibody, yet maintain a proclivity for the intracellular environment.  
As an alternative to antibodies, many small protein scaffolds have 
been identified, some derived from the antibody itself and others from 
unrelated polypeptide sequences, but which, like the antibody, contain 
hypervariable regions for epitope recognition (Figure 2.1). With respect 
to the ubiquibody technology, the collective group of these binders have 
been termed designer binding proteins (DBPs).  
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Figure 2.1: Diversity of DBPs.  
While all DBPs are small, compact proteins, they span a wide range of secondary and 
tertiary structure; target binding paratopes are unique to each DBP scaffold. (a) TPR 
binds targets using contacts from the surface generated by α-helical repeats. PDB ID: 
2C2L [21] (b) scFv binds targets using contacting the target via one face and the loop 
of three CDR regions. PDB ID: 1P4I [22] (c) DARPin contains variable residues in 
repeat loop and helix regions for target recognition. PDB ID: 5MA6 [23] (d) FN3 target 
diversity comes from randomization of the loop regions; though recent libraries also 
use one face. PDB ID: 3UYO [24]. Secondary structure (orange) of the DBP; DBP 
paratopes (blue) highlight the variable residues involved target recognition. 
Schematics were generated using PyMOL software. 
 
From any given DBP scaffold, specific binders can be selected for 
from libraries randomized at the key residues responsible for cognate 
epitope interaction [25], independently from other domains of the 
ubiquibody. (Theoretically, libraries derived from the full ubiquibody 
could also be made, though that approach has not been used in this 
project.) The primary binders reported here were selected for by ribosome 
[26, 27] and phage [28] display. In every case, regardless of scaffold 
origin, the DBP endowed the ubiquibody with its respective target 
specificity; the full list of DBPs incorporated into the ubiquibodies as of 
this report spans five different scaffolds, mammalian and bacterial target 
proteins, and is shown in Table 2.1.   
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Table 2.1: DBPs incorporated into the ubiquibody scaffold   
Scaffold Name Target Selection Ref 
TPR NCF-2 Rac None1 [29] 
scFv 
scFv13 β-galactosidase Immunization [30] 
13R4 β-galactosidase Bacterial selection [31] 
D10 gpD Bacterial selection/PCA [32] 
J21 JNK2 PCA 
GCN4 GCN4 Yeast two-hybrid [33] 
NAC32 α-synuclein Yeast surface display [34] 
C4 Huntington 
Phage display 
[35] 
Hag Hemagglutinin [36] 
3DX c-Myc [37] 
FN3 
YS1 MBP 
[38] YSX1 MBP 
GS5 GFP 
[24] 
GS2 GFP 
GL8 GFP 
GL6 GFP 
GL4 GFP 
AL2 Abl(SH2) 
AL38 Abl(SH2) 
DARPin 
OFF7 MBP 
Ribosome display 
[27] 
E40 ERK1/2 
[26] 
pE59 pERK1/2 
EpE82 ERK1/2 & pERK1/2 
EpE89 ERK1/2 & pERK1/2 
J1/2_2_25 JNK1/2 
[39] 
J1/2_2_3 JNK1/2 
J1_2_32 JNK1 
J1_4_7 JNK1 
J1_8_27 JNK1 
J2_3_29 JNK2 
VHH GFP4 GFP 
Immunization/ 
phage display [40] 
1NCF-2 is a naturally occurring TPR domain in human p67phox 
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Perhaps the most significant aspect of DBP-directed target 
specificity, is the capability to target subpopulations of protein families. 
Post-translationally modified proteins that could not be selectively 
studied by gene-knockout or RNAi are now differentiable with DBPs 
selected for specific protein isoforms [26].  
Notably, all ubiquibodies studied in this project derive their 
catalytic activity from an E3 U-box scaffold (see Chapter 3). Briefly, the 
U-box used in ubiquibodies was taken from human carboxy-terminus 
Hsc70 interacting protein (CHIP), which contains a tetratricopeptide 
repeat (TPR) domain to direct its natural target specificity. The TPR 
domain is critical to E3 function, both for target recognition and for the 
E3 dimer conformational changes needed to transfer ubiquitin from a 
charged E2 to a target [41]. This natural DBP functions in tandem with 
other domains of the E3, allowing the U-box catalytic domain to correctly 
position a charged E2 and catalyze the transfer of ubiquitin to an 
available surface lysine residue. Any DBP incorporated into a ubiquibody 
that uses the CHIP catalytic domain must be able to do the same.  
In previous work, we have shown that single-chain variable 
fragments (scFvs) and fibronectin type III domains (FN3s) are acceptable 
substitutes for CHIP’s native TPR domain [15]. Here, the first usage of 
designed ankyrin repeat proteins (DARPins) in ubiquibodies is reported 
and plays a prominent role in expanding the functionality of the 
ubiquibody technology. In this work, multiple types of DBPs have been 
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characterized as replacements for the TPR domain of CHIP. They have 
been evaluated based on the ability to recognize cognate targets and to 
facilitate the transfer of ubiquitin from an E2 to the target protein in vitro. 
The lower limit of scFv cognate target size has been investigated; a direct 
comparison of two different DBPS, an FN3 and a DARPin, against the 
same target has been made; and exploration into PTM-specific DARPins 
against a conserved kinase has been focused upon. 
 
Results 
Targeted ubiquitination of N-terminal Huntington peptide 
Poly-glutamine (poly-Q) containing proteins are interesting targets 
for directed ubiquitination, particularly with the elucidation of the 
ubiquitin code [42, 43], because poly-Q sequences are known to be 
resistant to degradation by eukaryotic proteasomes [44], which prefer 
proteolysis at acidic, basic, or hydrophobic residues [45]. Inclusion 
bodies that form from poly-Q aggregation, such as with mutant 
huntingtin or ataxin, also contain ubiquitin and components of the UPP 
[46]. Investigation into the ubiquitination patterns of these proteins may 
be important towards fully understanding diseases, such as Huntington’s 
and spinocerebellar ataxia, that result from mutations  extending poly-Q 
sequences [47].  
For ubiquibodies, the huntingtin protein offered an opportunity to 
investigate the minimum size for cognate targets of scFv-driven 
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ubiquibodies. We sought to create a ubiquibody specific for the N-
terminal product of the first exon of the Huntington (HTT) exon 1 gene by 
genetically fusing scFvC4 to CHIPΔTPR to generate C4-uAb. Residues 1-
17 of the huntingtin protein product from exon 1 of the HTT gene 
(Appendix A.3) form an amphipathic helix, N17, that immediately 
precedes the poly-Q sequence beginning at Q18 [48]. The crystal 
structure of the scFvC4, in complex with the N17 peptide has been solved 
and the three lysine residues (K6, K9 and K15) of N17 are shown to be 
solvent accessible (Figure 2.2a).   
scFvC4 directed binding of the N17 peptide was shown by enzyme-
linked immunosorbent assay (ELISA) (Figure 2.2b). Both the scFv and 
ubiquibody bound well to the N17 peptide. Interestingly, the catalytic 
domain, CHIPΔTPR, also bound the peptide, despite the lack of a DBP. 
This suggests a secondary interaction of the peptide with CHIPΔTPR; 
theoretically, the peptide’s amphipathic helix could interact with the 
amphipathic helices of the coiled-coil domain. To test whether N17 could 
be ubiquitinated by the C4-uAb, in vitro ubiquitination assays were 
performed (Figure 2.2c). No ubiquitination of the huntingtin N17 peptide 
was detected in the presence of C4-uAb. Anti-ubiquitin detection shows 
that the C4-uAb is an active E3 ubiquitin ligase, and the poly-ubiquitin 
bands likely correspond to auto-ubiquitination. Mono-auto-
ubiquitination of C4-uAb was confirmed by anti-His detection of 
ubiquibody species. 
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Figure 2.2: Characterization of the C4-uAb.  
(a) Sequence and structure of the N17 huntingtin peptide (yellow) complexed with 
scFvC4 (orange). The VH domain of the scFv (bright orange) interacts with the 
amphipathic helix of the N17 peptide; the three lysine residues of N17 (yellow spheres) 
are solvent accessible. PDB ID: 4RAV [48]. (b) ELISA analysis of N17 interaction with 
immobilized C4-uAb, scFvC4, and CHIPΔTPR. (c) In vitro ubiquitination assay of N17 
peptide by C4-uAb. At the indicated times, reaction aliquots were removed and 
immunoblotted with the indicated antibodies.  
 
This data suggests that seventeen residues may be outside the 
ubiquitinate-able size range for CHIPΔTPR, when guided by an scFv. To 
date, the largest protein complex to be successfully ubiquitinated by a 
ubiquibody is E. coli β-galactosidase, a 116 kDa protein that assembles 
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into a homotetramer of ~470 kDa. The smallest protein to be 
ubiquitinated with an scFv-based ubiquibody is bacteriophage capsid D 
(gpD), 16 kDa [49]. Taken together with the findings here, the minimum 
target size for successful ubiquitination by ubiquibodies—composed of 
an scFv DPB and the CHIPΔTPR catalytic domain—likely lies between 2-
16 kDa, although the number of surface accessible lysine residues will 
play an important role.  
Functional evaluation of an FN3- versus a DARPin 
To address the question of which DBP scaffold is best suited for 
directed target specificity, while retaining E3 catalytic activity, a DARPin 
and an FN3 specific against the same target were tested in vitro and in 
situ. The FN3, YS1, was developed against bacterial maltose binding 
protein (MBP) using phage display by the Koide group [38]. YS stands for 
the tyrosine/serine binary code that was used to evolve binding; the 
annotated sequence for YS1 is shown in Appendix A.4. YS1 binds MBP 
with nanomolar affinity, primarily due to a slow off-rate (Table 2.2). The 
DARPin, OFF7, was also raised against MBP, but by ribosome display by 
the Plückthun group [27], (Appendix A.5). OFF7 has a similar on-rate 
against MPB, though it’s off-rate is approximately thirty-fold slower than 
YS1, leading to KD in the low nanomolar range. Due to the large structural 
differences between the two DBPs, it is conceivable that transfer of 
ubiquitin by the U-box catalytic domain will be better facilitated by one 
scaffold or the other.  
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Table 2.2: DBP affinity for MBP  
DBP ka M-1s-1 
kd 
s-1 
KD 
nM 
YS1 7.5 × 105 5.4 × 10-2 73 
OFF7 4.2 × 105 1.9 × 10-3 4.4 
Binding data for YS1 from Gilbreth et al. [38] and for OFF7 from Binz et al. [27]. 
 
 
 
Figure 2.3: Functional evaluation of an FN3- versus a DARPin-uAb in vitro.  
(a) DBP-directed binding of MBP measured by ELISA. Immobilized MBP was tested for 
interaction with YS1-uAb and OFF7-uAb, as compared to the catalytic domain alone. 
The DARPin-based ubiquibody, OFF7-uAb, bound with higher affinity than the FN3-
based ubiquibody, YS1-uAb. The catalytic domain, CHIPΔTPR did not bind above 
background until concentrations greater than 10μM. (b) In vitro ubiquitination of 
MBP. At the indicated times, aliquots were boiled with loading buffer to halt the 
reaction, then immunoblotted with the indicated antibody.  
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To test whether FN3s and/or DARPins retained the ability to bind 
MBP when fused to CHIPΔTPR, ELISA analysis was used (Figure 2.3a). 
Purified OFF7-uAb bound MBP with higher affinity than YS1-uAb, 
though both DPBs were able to redirect ubiquibody specificity. The 
catalytic domain alone (CHIPΔTPR) did not bind MBP without the aid of 
a DBP. These results suggest that neither FN3 nor DARPin function is 
inhibited by C-terminal fusion to CHIPΔTPR. 
Functional E3 catalytic activity was confirmed by incubation of 
OFF7-uAb and YS1-uAb with purified components of the UPP (E1, E2, 
ubiquitin, and ATP) and MBP, followed by immunoblot to visualize 
ubiquitination of the target (Figure 2.3b). With the OFF7-uAb, mono-
ubiquitination of MBP was observed as early as 5 minutes and poly-
ubiquitination after 30 minutes. With YS1-uAb, only mono-
ubiquitination was observed, and only after 60 minutes. This data 
suggests that the DARPin was better suited—either structurally and/or 
functionally within the fusion protein—to facilitate the transfer of 
ubiquitin from the E2 to the target, across the ubiquibody scaffold.  
Because MBP can be ubiquitinated in the presence of components 
of the UPP, MPB should be directed to the proteasome by ubiquibody 
activity in vivo. We hypothesized that the effectivity of the DARPin-uAb 
may be higher than the FN3-uAb, due to its higher rate of ubiquitination 
in vitro. In order to test whether the MBP can be redirected to the 
proteasome in mammalian cells, MBP alone, or with either YS1-uAb or 
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OFF7-uAb, was ectopically expressed in HEK293T cells (Figure 2.4a and 
b). Co-expression of MBP with either ubiquibody led to target degradation 
in a titratable manner. Oddly, silencing of MBP by the OFF7-uAb was 
inversely proportional to the DNA transfection levels; comparatively, YS1-
uAb was able to silence MBP, in a manner directly proportional to DNA 
transfection levels [15]. Notably, OFF7-uAb required 100-fold lower 
amounts of transfected DNA, compared to YS1-uAb, to achieve optimal 
silencing, so when initial testing of the OFF7-uAb was performed, it was 
assumed to be inactive in mammalian cells [49], though the data here 
suggest otherwise. To ensure that the degradation levels were related to 
productive ubiquitination efficiency and not ectopic protein expression, 
the levels of OFF7-uAb were compared to YS1-uAb after transfection with 
equal molar amounts of DNA (Figure 2.4c). Both ubiquibodies were 
expressed from the same mammalian expression vector, pcDNA3, under 
the same promoter. YS1-uAb was expressed at a much higher level than 
OFF7-uAb, suggesting that OFF7-uAb’s ability to silence MBP, even at 
much lower target:ubiquibody transfection ratios, was not due to 
superior protein expression. However, at optimal transfection ratios, both 
OFF7-uAb and YS1-uAb led to comparable silencing of MBP (Figure 
2.4d). These results demonstrate that both DARPin- and FN3-based 
ubiquibodies are capable of targeted protein silencing in mammalian 
cells, but the necessary dynamic range of ectopic protein expression 
changes depending on the type of DBP used.   
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Figure 2.4: Silencing of MBP by YS1-uAb and OFF7-uAb in situ.  
HEK293T cells were transfected with expression vectors encoding MPB, GFP, YS1-
uAb, and/or OFF7-uAb; additional empty vector was used to balance the DNA levels. 
Cells were transfected with a 2:1 ratio of transfection agent:total DNA (ng) and 
incubated for 24hrs post-transfection. Samples were harvested and analyzed by 
immunoblot with the indicated antibodies; gel loading was normalized by total protein 
and confirmed by β-tubulin or GAPDH levels. (a) Silencing of MBP by OFF7-uAb. (b) 
Silencing of MBP by YS1-uAb. In (a) and (b), differing amounts of transfected 
ubiquibody DNA led to variable decreases in soluble MBP levels. (c) Expression of 
OFF7-uAb and YS1-uAb in HEK293T cells. (d) In situ silencing of MBP. Ectopically 
expressed MBP was silenced by both OFF7-uAb and the YS1-uAb. A native target of 
CHIP, Hsp70, was unaffected by uAb expression. Transfection uniformity was checked 
by GFP-expression. 
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Development of PTM-specific ubiquibodies 
As outlined earlier, one of the primary milestones in the 
advancement of protein-level silencing is post-PTM resolution. The most 
common PTM is phosphorylation, with upwards of 25% or all proteins 
being phosphorylated [50]. In order to differentiate the non-
phosphorylated from the phosphorylated isoforms of a protein, DBPs that 
selectively bind epitope or conformational differences between the two are 
needed. Near the beginning of this project, DARPins against a kinase, its 
non-phosphorylated isoform, and its phosphorylated form were identified 
by ribosome display [26]. Subsequently, we hypothesized that these 
phospho-specific DARPins could be used to generate phospho-specific 
ubiquibodies [51].  
Extracellular-signal regulated kinase (ERK) is an essential protein 
in mammalian cells that activates upon a double phosphorylation event 
[52]. ERK1/2 are part of the mitogen activated protein kinase (MAPK) 
cascade that transduces and amplifies growth signals from the cell 
surface into the nucleus (Figure 2.5). The MAPK pathway tends to be 
upregulated in at least 30% of cancers, making its components ideal 
targets for protein silencing [53].  
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Figure 2.5: MAPK pathway.  
Canonical MAPK activation upon signal detection includes three level (MAPKKK, 
MAPKK, and MAPK) phosphorylation signal transduction. ERK1/2 are kinases that 
function at the MAPK level of signaling.  
 
Kummer et al. reported DARPins specific for inactive forms of the 
kinase (E40), specific for active doubly-phosphorylated kinase (pE59), 
and unspecific for PTM isoforms of ERK (EpE89 and EpE82), including 
co-crystal structures of E40 in complex with ERK2 and pE59 in complex 
with phosphorylated ERK2 (pERK2) [26]. Unsurprisingly, both DARPins 
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bound ERK near the Thr185/Tyr187 active site, where epitope 
differences between ERK2 and pERK2 are greatest. The respective 
affinities and specificities of these DARPins are shown in Table 2.3.  
 
Table 2.3: Affinity of PTM-specific DARPins for ERK2/pERK2 
DBP KD: ERK2 nM 
KD: pERK2 
nM Specificity 
E40 6.6 1200 182 
pE59 >8700 117 74 
EpE89 - - None 
EpE82 - - None 
Data from Kummer et al. [26]. 
 
The DARPins identified in this screen were used to construct a 
suite of four ERK-specific ubiquibodies (E40-uAb, pE59-uAb, EpE89uAb, 
and EpE82-uAb). To test whether the ERK-ubiquibodies inherited their 
parent phospho-specificity, ELISA analysis of the ubiquibodies against 
ERK2 and pERK2 was performed (Figure 2.6). Isoform-specific DARPins 
retained their specificity when C-terminally fused to CHIPΔTPR; 
furthermore, the fusion seems to universally increase affinity, without 
affecting specificity. E40-uAb bound immobilized non-phosphorylated 
ERK2 with higher affinity than pERK2. Conversely, the pE59-uAb bound 
pERK2 with higher affinity than non-phosphorylated ERK2. EpE89-uAb 
bound both isoforms of ERK2 with comparable affinity. The three 
ubiquibodies bound their respective preferred target(s) with similar 
affinity. The unfused DARPins bound the expected targets, albeit at much 
lower affinities than the ubiquibodies (except for DARPin EpE89 which 
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bound pERK2 with significantly higher affinity than ERK2). Notably, both 
E40-uAb and pE59-uAb bound their non-cognate isoform, pERK2 and 
ERK2 respectively, with affinities higher than background. This is 
consistent with the findings of Kummer et al. that show E40 and pE59 
retain micromolar affinities for their non-cognate isoform of ERK 
respectively [26].  
The improvement of binding upon fusion with the catalytic domain 
CHIPΔTPR suggests that the DARPin-target interaction is stabilized by 
the addition of a C-terminal fusion. Ironically, the DARPins did not bind 
to ERK in vitro when a C-terminal Flag-His6 was used (data not shown). 
Alternatively, dimerization by the ubiquibody may play a role in increased 
signal detection. The ability to preferentially detect one isoform versus 
another, differing only in two –PO4 moieties of otherwise identical 
proteins, was an important first step in the generation of PTM-specific 
ubiquibodies. 
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Figure 2.6: Binding specificity analysis of PTM-specific ubiquibodies.  
Full ELISA curves of purified DARPins and ubiquibodies against immobilized (a) ERK2 
or (b) pERK2. (c) Binding comparison of DARPins and DARPin-uAbs to ERK2 and 
pERK2 at 100nM. The E3 catalytic domain lacking a DBP, CHIPΔTPR, served as a 
negative control. [15] 
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Evaluation of PTM-specific ubiquibodies 
To determine if phospho-specificity of the DBP leads to preferential 
ubiquitination of ERK and pERK, in vitro ubiquitination assays were 
performed (Figure 2.7 and Figure 2.8). Ubiquitination of both isoforms 
was observed in the presence of either E40-uAb, pE59-uAb, or EpE89-
uAb. Slightly stronger mono-ubiquitination of ERK2 was seen as early as 
5 min with E40-uAb, compared to pE59-uAb or EpE89-uAb. Strong poly-
ubiquitination smears were observed after 30 min for the pE59-uAb and 
EpE89-uAbs, and after 60min for the E40-uAb. Auto-ubiquitination of 
only the pE59-uAb was observed, though not of the E40-uAb or EpE89-
uAb (though this may have been an artifact of detection of the ubiquibody 
through its Flag tag, which contains a ubiquitinatable lysine moiety). 
Ubiquitination of pERK2 yielded similar results, with pE59-uAb and 89-
uAb showing faster formation of poly-ubiquitin species than the E40-
uAb, though all three ubiquibodies showed target ubiquitination as early 
as 5min.  
These results show that effective ubiquitination of ERK2 and 
pERK2 can be achieved in the presence of excess UPP pathway 
components, despite affinity differences between the DBPs. Furthermore, 
the dynamic range for ubiquitination by the U-box in general must 
minimally span nanomolar to micromolar target affinities. Future 
investigations into the kinetics of uAb-target-E2 interactions could 
illuminate the optimal DBP:target affinity, though secondary affinities for 
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non-cognate targets will need to be minimized lower than micromolar 
ranges (see Chapter 5). 
 
 
Figure 2.7: In vitro ubiquitination of ERK2.  
Immunoblots of in vitro ubiquitination assays of ERK2 with (a) E40-uAb, (b) pE9-uAb, 
and (c) EpE89-uAb. Reactions were halted at the indicated time points and analyzed 
with the indicated antibodies.  
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Figure 2.8: In vitro ubiquitination of pERK2.  
Immunoblots of in vitro ubiquitination assays of pERK2 with (a) E40-uAb, (b) pE9-
uAb, and (c) EpE89-uAb. Reactions were halted at the indicated time points and 
analyzed with the indicated antibodies. 
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The ability of the ubiquibodies to interact with endogenous ERK 
species was confirmed by pulldown assay of HEK293T cell lysate (Figure 
2.9). Purified DARPins interacted strongly with endogenous ERK1 and 
ERK2; the corresponding ubiquibodies also interacted with ERK1/2 
though at lower levels. E40-uAb showed a preference for ERK2 over 
ERK1, while pE59 and pE89 were unspecific for either homolog. EpE82-
uAb did not pulldown endogenous target above background levels. 
Neither a non-specific ubiquibody, OFF7-uAb, nor the catalytic domain 
alone, CHIPΔTPR, interacted with endogenous ERK species.  
 
 
Figure 2.9: Pulldown assay of ERK-ubiquibodies from HEK293T cells.  
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Immunoblots of captured uAbs and control proteins incubated with HEK292T cell 
lysate. ERK-DARPins and –uAbs interacted with endogenous ERK1/2, while non-
specific ubiquibody and CHIPΔTPR did not.  
 
Next, to check for soluble expression of ubiquibodies in 
mammalian cells, HEK293T cells were transiently transfected with 
plasmid DNA encoding either E40-uAb, pE59-uAb or EpE89-uAb (Figure 
2.10). Ubiquibody expression 24hrs post-transfection was detected by 
the His6 tag of the ubiquibody; all three ubiquibodies were expressed at 
detectible levels, though E40-uAb was expressed at significantly lower 
levels than either pE59-uAb or EpE89-uAb. This lower expression may 
be tied to the basic structure of DARPin E40, which contains three 
ankyrin repeats, as opposed to two, as pE59 and EpE89 do. (OFF7-uAb, 
whose DBP is also a DARPin of three repeats, was similarly less well-
expressed compared to other ubiquibodies, Figure 2.4c.)  
 
 
Figure 2.10: Expression of DARPin ubiquibodies in HEK293T cells.  
Immunoblot of HEK293T cells transiently transfected with pcDNA3-uAb vectors and 
detected with the indicated antibody.  
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In order to test the ubiquibodies’ ability to silence ERK in vivo, 
HEK293T cells were again transiently transfected with plasmid DNA 
encoding either EpE89-uAb, E40-uAb, or pE59-uAb (Figure 2.11). 
Samples were analyzed by immunoblot 24hrs after transfection for 
global, soluble ERK levels. Expression of the EpE89-uAb significantly 
lowered ERK levels in living cells (Figure 2.11a and b). Interestingly, 
ERK1/2 levels were inversely proportional to ubiquibody transfection 
levels, and scaled linearly with the amount of transfected DNA. This is 
similar to results seen with OFF7-uAb against ectopically expressed MBP, 
suggesting that the effect is an effect of DARPin-based ubiquibody 
mediated silencing and not related to the source of target protein 
expression.  
Phospho-specific ubiquibodies were also tested for effect on 
endogenous ERK levels. Ectopic expression of the E40-uAb led to no 
measurable silencing of ERK1/2 (Figure 2.11c). Since the relative 
expression of E40-uAb was much lower than either of EpE89-uAb or 
pE59-uAb, it is possible that the level of ubiquibody expression that 
would lead to measurable silencing was outside the parameters of this 
assay. Surprisingly, ectopic expression of the pE59-uAb resulted in near 
complete silencing of global ERK1/2 levels in cells (Figure 2.11d). 
Ectopic expression of neither DARPins E40 and pE59 nor the U-box 
domain, CHIPΔTPR, alone affected endogenous ERK1/2 levels. 
Importantly, a downstream substrate of ERK1/2 signaling, Mnk, was 
33 
 
unaffected by the presence of pE59-uAb and resultant silencing of 
ERK1/2, indicating targeted specific activity of the ubiquibody in the 
presence of the full MAPK pathway. Collectively, these data show that 
effective silencing of endogenous targets is closely tied to expression 
levels of the ubiquibody, and the affective range of which may be tied to 
DBP-determined affinity. And, although pE59-uAb was theorized to 
specifically silence pERK, both the EpE89-uAb and pE59-uAb are 
functional silencers of an endogenous target protein [51].  
Because in vitro ubiquitination, as visualized by immunoblot, did 
not correlate to equal silencing effects by the ubiquibodies in vivo, we 
sought to elucidate the ubiquitination profile of ERK by each ubiquibody. 
High molecular weight products (50-250kDa) from in vitro ubiquitination 
reactions with the E40-uAb, pE59-uAb, and EpE89-uAb were analyzed 
by mass spectrometry (Figure 2.12). As previously seen by immunoblot, 
ubiquitination sites on both ERK2 and pERK2 were identified for all three 
ubiquibodies. The ubiquitination profiles of the ubiquibodies overlapped 
significantly and preferentially ubiquitinated one face of (p)ERK2 
(oriented forward in Figure 2.12b and d). This preferred face consisted 
of the plane formed by N- and C-lobes near the active site of ERK2,  which 
correlated with the positioning of the C-terminus of the DARPins seen in 
co-crystal structures with ERK2 [26], and would thus be located in 
closest proximity to CHIPΔTPR when bound by the ubiquibody fusion 
protein (Figure 2.13).   
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Figure 2.11: Silencing of endogenous ERK in HEK293T cells.  
Representative immunoblots of extracts prepared from HEK293T cells transfected 
with, μg plasmid DNA per well, (a) pcDNA3-EpE89-uAb at 1.0, 0.5, 0.25 and 0.125 (c) 
pcDNA3-E40-uAb at at 1.0, 0.5, 0.25 and 0.125, and pcDNA3-E40 at 1.0, (d) pcDNA3-
pE59-uAb at 2.0, 1.0, 0.5, and 0.25, and pcDNA3-pE59 and pcDNA3-CHIPΔTPR at 
2.0. Transfection were balanced with empty pcDNA3 vector and cells were harvested 
24 hr post-transfection. Lanes were normalized by total protein content and confirmed 
by β-Tubulin immunoblot. (b) Silencing of global ERK levels by the EpE89-uAb. Bars 
were generated by averaging densitometry analyses from three independent 
experiments using Image Lab software [15]. 
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Figure 2.12: Ubiquitination profiles of ERK and pERK.  
(a and b) Occupancy rate of –GG modification of ERK2/pERK2 lysine residues by 
mass spectrometry. Bars were generated by normalizing ubiquitinated residue counts 
relative to total residue counts then by overall target ubiquitination frequency, and by 
averaging across three independent experiments. Ubiquitinated peptide counts of 
peptides containing more than one non-C-terminal lysine residue were averaged over 
all non-C-terminal lysines. (c and d) Map of ubiquitination sites on ERK2 and pERK2 
respectively. ERK2/pERK2 backbones are shown as ribbons (white), with lysines not 
covered by mass spectrometry analysis (dark grey spheres) and lysines not identified 
as ubiquitinated (light grey spheres). Lysines identified as ubiquitinated are 
represented as spheres colored by decreasing saturation with decreasing frequency of 
ubiquitination, with sites modified by EpE89-uAb (green), E40-uAb (blue), and pE59-
uAb (red). Crystal structures from (b) PDB ID: 3ZU7 and (c) PDB ID: 3ZUV [26]. 
 
A total of eight lysine residues were found to be ubiquitinated on 
ERK2, and a subset of seven of those were ubiquitinated on pERK2, 
despite the presence of twenty-three surface exposed lysines in the 
crystal structure of ERK2. Of the ubiquitinated lysines, four (K99, K340, 
K342, and K344) were clustered in the three-dimensional structure of 
ERK2, suggesting an optimal orientation of the charged E2 (Ube2D1) 
relative to the target surface. Only one lysine, K259, was ubiquitinated 
in ERK2 and not pERK2, suggesting that the conformational changes 
upon phosphorylation reposition K259 away from the U-box-bound, 
ubiquitin-charged E2. K203 and K330 were among the most often 
ubiquitinated lysines, despite being located away from the lysine cluster, 
though both were located on the same face of ERK2. K48 was both one 
of the least often ubiquitinated residues and the only lysine not on the 
same face of ERK to be ubiquitinated.  
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Figure 2.13: Orientation of U-box domain in ERK-uAb complex.  
Cartoon diagram of potential domain arrangement of the ubiquibody relative to the 
target. The flexible linker is genetically fused to the C-terminus of the DARPin, and the 
N-terminus of CHIPΔTPR. The plane of ubiquitination is in direct proximity to the 
theoretical position of the catalytic domain. Schematics were generated using PDB ID: 
2C2L [21] and 3ZU7 [26] and Pymol software.  
 
Of the three ubiquibodies, pE59-uAb showed the most drastic 
change in its ubiquitination profile from ERK2 to pERK2. pE59-uAb 
showed high levels of ubiquitination of K259 that was completely 
abolished upon phosphorylation of the substrate. Conversely, pE59-uAb 
showed no ubiquitination of K99 in the non-phosphorylated form of 
ERK2, but showed low levels of ubiquitination of the same residue in 
pERK2.  The E40-uAb was the only ubiquibody that did not ubiquitinate 
K259 in ERK2; the ubiquitination profile of E40-uAb also changed 
between ERK2 and pERK2, ubiquitinating K48 in ERK2 but not pERK2. 
Ubiquitination of K340 by the E40-uAb was also reduced between ERK2 
and pERK2. Similar to the pE59-uAb, the EpE89-uAb did not 
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ubiquitinate K259 in the phosphorylated form of ERK2, although the rest 
of its ubiquitination profile remained similar between ERK2 and pERK2. 
Notably, all three ubiquibodies showed similar ubiquitination profiles of 
ubiquitin, preferentially forming K6, K11, K48, and K63 poly-ubiquitin 
linkages in the presence of the E2 Ube2D1 (see Chapter 3). 
Taken together, these results suggest that even highly similar 
ubiquibodies can have significantly different target ubiquitination 
profiles, which may be responsible for the dramatically different silencing 
capabilities of the ubiquibodies in vivo. All three of the DARPins reported 
here bind the same epitope of ERK2 [26], suggesting that the observed 
differences in silencing and ubiquitination are not the result of radical 
repositioning of the U-box catalytic domain relative to the target. The 
small differences in catalytic efficiency in combination with large 
differences in affinity of each ubiquibody are likely responsible for the 
resultant silencing of endogenous targets.  
As ERK1/2 are both essential, highly-regulated proteins, silencing 
them for long periods of time may prove difficult, as cells will naturally 
attempt to return their activity to base levels. To determine the effective 
time frame of ubiquibody-mediated silencing, HEK293T cells were 
transiently transfected with EpE89-uAb and incubated for 72hrs (Figure 
2.14). At 24hr and 48hrs, effective EpE89-uAb dependent silencing of 
ERK1/2 was observed, though expression of the ubiquibody decreased 
marginally. After 72hrs, the amount of ERK1/2 protein returned to levels 
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comparable to cells transfected with empty vector. These results show 
that silencing of essential proteins can be ameliorated over time in living 
cells, despite continued presence of the ubiquibody.   
 
 
Figure 2.14: Silencing of ERK in mammalian cells over time.  
Immunoblots of whole cell lysate of HEK293T cells transfected with either empty 
pcDNA3 or pcDNA3-EpE89-uAb. Cells were harvested at the indicated time points and 
analyzed with the indicated antibodies. [51] 
 
Discussion 
The designer binding protein is one of the two essential domains of 
engineered E3 ubiquitin ligases. Because DBPs are not limited to a single 
scaffold, they offer near unlimited variability to ubiquibody construction. 
In this report, limitations to the target size have been bracketed, 
comparisons between different DBP scaffolds against the same target 
substrate have been made, and the first attempt at post-PTM resolution 
silencing has been executed. The affinity of the DBP within the 
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ubiquibody scaffold has recurred as an important feature for successful 
target ubiquitination and subsequent silencing in vivo, though its effects 
have not been investigated directly.  
Ironically, much of the ongoing research into DPBs focusses on 
identifying binders that have the highest possible affinities, often 
approaching low picomolar ranges [22, 54, 55]. The inability of the E40-
uAb to silence a target to which it has low nanomolar affinity, while 
similar ubiquibodies with lower affinities to the same target are functional 
silencers, suggests that an optimal range of target affinity exists for 
ubiquibodies. The differential expression levels of OFF7-uAb and YS1-
uAb required to silence the same target support this hypothesis. Indeed, 
most biological interactions take place in the high nanomolar to 
micromolar range [56]. Alternatively, in this case, there may be inherent 
differences in the ability of FN3-based ubiquibodies versus DARPin-based 
ubiquibodies to silence proteins that stem from differences in DBP 
structure and not affinity. 
While perfect PTM-specific silencing by ubiquibodies has not been 
achieved as of yet, significant steps have been made towards generating 
phospho-specific silencers of endogenous ERK. Indeed, in the course of 
this project, the first ubiquibodies against an endogenous target have 
been successfully tested. In order to expand the range of PTM-specific 
silencing, further screening of DBPs will need to be made with careful 
attention to selection against non-preferred target isoforms. Notably, 
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PTM-specific antibodies are directly adaptable into the scFv format, so 
recent advancements made in PTM-specific antibodies are a rich source 
of potential for PTM-specific ubiquibodies [3]. Further exploration into 
the ERK versus pERK silencing effects of the phospho-specific 
ubiquibodies will help to better understand the expression and kinetic 
requirements of PTM-specific ubiquibodies 
While this report focuses on the fusion of DBPs to a U-box catalytic 
domain, the modular nature of the ubiquibody allows for other catalytic 
domains to be used. The optimal type of DBP may change depending on 
the other domains of the ubiquibody. As for CHIPΔTPR, all tested types 
of DBP can function as substitutes of the native TPR, ranging from scFvs 
to FN3s to DARPins.  
 
Materials and Methods 
Genes and plasmid construction. Ubiquibodies, targets, and 
control proteins were cloned following the design and protocol outlined 
previously [15]. The following genes were provided as kind gifts from other 
labs: DARPin OFF7, from Marc Ostermeir (Johns Hopkins); YS1, from 
Shohei Koide (University of New York); DARPins E40, pE59, EpE89, 
EpE82, pLV-ERK2-Avi, pLV-MEK1R4F-ERK2-His-Avi, from Andreas 
Plückthun (University of Zurich); full length human CHIP, from Cam 
Patterson (Weill Cornell Medical Center); pSP10B BirA, from Amy 
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Karlsson (University of Maryland). scFvC4 was synthesized by GenScript 
based on NCBI sequences.  
Bacterial Expression Vectors: All ubiquibodies were cloned into 
pET28a(+) between the NcoI and HindIII sites, in the format NcoI-ATG-
DBP-EcoRI-GSGSG-CHIPΔTPR-SalI-Flag-His6-Stop-HindIII. DBPs were 
PCR amplified, introducing a 5’ NcoI site and start codon and 3’ EcoRI 
codon, followed by double digestion of the product and backbone, 
pET28a(+)-R4-uAb, with NcoI/EcoRI, and subsequent ligation to yield  
pET28a(+)-DBP-uAb vectors. (Due to an internal EcoRI site in the FN3 
monobody YS1, overlap extension PCR was used to add the GSGSG linker 
and N-terminus of CHIPΔTPR to the YS1 PCR product, until reaching a 
unique BstBI site within CHIPΔTPR. This overlap extension PCR product 
was then ligated between NcoI and BstBI sites of pET28a-R4-uAb, 
yielding pET28a-YS1-uAb.) 
Control scFvs, FN3s, and OFF7 were similarly cloned into 
pET28a(+) between the NcoI and HindIII sites, in the format NcoI-ATG-
DBP-SalI-Flag-His6-Stop-HindIII. Cloning was the same as for the 
ubiquibodies, except during PCR amplification a 3’ SalI site was 
introduced instead of the EcoRI, and subsequent double digestion, with 
NcoI/SalI, and ligation. Control DARPins (with the exception of OFF7) 
were cloned into pET28a(+) between NcoI and HindIII sites in the format 
NcoI-ATG-RGS-His6-BamHI-DARPin-N-Stop-HindIII, using PCR 
amplification, followed by double digestion with NcoI/HindIII and ligation 
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to yield pET28a(+)-DBP vectors. CHIP∆TPR was cloned into pET28a(+) in 
the format NcoI-ATG-CHIPΔTPR-SalI-Flag-His6-Stop-HindIII by PCR 
amplification of DNA corresponding to amino acids 128-303 of human 
CHIP, with introduction of a 5’ NcoI site and a 3’ SalI site. Double ligation 
was performed as above to insert this product into the backbone 
pET28a(+)-R4-uAb to yield pET28a(+)-CHIPΔTPR. 
Mammalian expression vectors: All ubiquibodies and control 
proteins were cloned into pcDNA3 between the HindIII and XbaI sites by 
PCR amplification of the respective pET28a(+) vector, introducing a Kozak 
sequence at the start codon, and subsequent double digestion with 
HindIII/XbaI and ligation into backbone pcDNA3. The target substrate 
protein MBP was similarly cloned into pcDNA3 between HindIII and XbaI.  
Protein expression and purification. All purified proteins were 
obtained from cultures of E. coli BL21(DE3) cells grown in Luria-Bertani 
(LB) medium. For biotinylated proteins, expression plasmids were co-
transformed with pSP10B-BirA. Expression was induced with 0.1mM 
IPTG when the culture density (Abs600) reached 0.6-0.8 and proceeded at 
30°C for 6hr, after which cells were harvested by centrifugation at 
4,000×g for 20min at 4°C. The resulting pellets were stored at -80°C 
overnight. Thawed pellets were resuspended in 15mL buffer (PBS, 10mM 
imidazole, pH 7.4) and lysed with a high-pressure homogenizer (Avestin 
EmulsiFlex C5). Lysates were cleared by centrifugation at 20,000×g for 
20 min at 4°C. His6-tagged proteins were subjected to gravity Ni2+-affinity 
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purification HisPurTM Ni-NTA Resin (Thermo, 88221) following 
manufacturer’s protocols. Samples were desalted into buffer (PBS, pH 
7.4) using PD 10 Desalting Columns (GE Healthcare, 17-0851-01) 
following manufacturer’s protocols. Samples were stored at 4°C for up to 
two weeks or diluted to 25% glycerol and stored at -80°C indefinitely. For 
biotinylated proteins, a second purification step was performed using 
Pierce Monomeric Avidin Agarose (ThermoFisher, 20228) according to 
manufacturer’s protocols followed by desalting and storage as above.   
Protein analysis. SDS-PAGE and immunoblotting of proteins was 
performed according to standard procedures. BioRad Coomassie R-250 
stain was used to visualize proteins in SDS-PAGE (BioRad, Mini-
PROTEAN® TGX). The following primary antibodies were utilized for 
immunoblotting: rabbit anti-huntingtin (Abcam, ab451669), mouse anti-
MBP-HRP (NEB, E8038), rabbit anti-ERK (Cell Signaling Technology, 
9102), rabbit anti-pERK (Cell Signaling Technology, 9101), mouse anti-
ubiquitin (Millipore, P4D1-A11), rabbit anti-His6-HRP (Abcam, ab1187), 
rabbit anti-β-tubulin (Cell Signaling Technology, 5346), rabbit anti-Flag-
HRP (Abcam, ab49763). Secondary antibodies goat anti-rabbit IgG (H+L) 
and anti-mouse IgG (H+L) with HRP conjugation (Promega) were utilized 
as needed.  
Enzyme linked immunosorbent assay (ELISA). For ELISA 
analysis of huntingtin and MBP, a previously established protocol was 
modified to detect binding to huntingtin and MBP [15]. Briefly, a 96-well 
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EIA plate was coated overnight at 4°C with 100μL C4-uAb, scFvC4, 
CHIPΔTPR, or PBS (for huntingtin) or 100μL MBP at 4μg/mL in PBS. The 
plate was then washed three times with 100μL PBST (1×PBS + 0.1% 
Tween20) per well for 5min with shaking and blocked with 100μL 
blocking buffer (PBS + 5% milk) per well at room temp, slowly mixing for 
2hr. Purified protein samples were introduced in blocking buffer as serial 
dilutions with 50μL per well and incubated at room temp slowly mixing 
for 1hr. Three PBST washes were used to remove non-bound protein 
before introducing 50μL of anti-Flag-huntingtin (diluted 1:1000 in PBS) 
followed by anti-rabbit-HRP (1:2500) (huntingtin) or anti-His6-HRP 
(1:10000) (MBP) and incubating at room temp with slow mixing for 1hr. 
Six final PBST washes were performed before incubation with 200μL OPD 
(Sigma Fast tablets) in the dark for 30min. The reaction was then 
quenched with 50μL 3N H2SO4 and absorbance read at 490nm.  
For ERK and pERK ELISA analysis, a previously established 
protocol was used [26]. Briefly, all steps until detection were performed 
at 4°C. Biotinylated ERK2 and pERK2 diluted in coating buffer (PBS, 
1mM DTT, 0.05% Tween20) were immobilized on NeutrAvidin coated 96-
well plates (Pierce) overnight at 4°C. Plates were washed twice with 200μL 
coating buffer and then blocked with block buffer (coating buffer + 5% 
BSA) for 1hr. Plates were washed three times with 200μL coating buffer, 
introduction of the ubiquibody or control protein diluted in coating buffer 
to the indicated concentrations and incubated for 1hr. Plates were 
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washed three times with wash buffer (PBS, 0.05% Tween20), before 
introducing anti-RGS-His4 (1:5000) for 1hr, followed by anti-rabbit-HRP 
(1:2500) for 1hr, washing three times between and after incubation with 
wash buffer. Incubation with 200μL OPD (Sigma Fast tablets) was 
performed in the dark for 30min. The reaction was then quenched with 
50μL 3N H2SO4 and absorbance read at 490nm.  
In vitro ubiquitination assays. Ubiquitination assays were 
performed as previously described [41] in the presence of 0.1μM purified 
human recombinant Ube1 (R&D Systems, E-305), 4μM human 
recombinant UbcH5α/Ube2D1 (R&D Systems, E2-616), 3μM uAb, 1.5μM 
human ERK2-GST (ThermoFisher, PV3314) or MBP (NEB) or huntingtin 
(provided by Alyse Portnoff), 50μM human recombinant ubiquitin (R&D 
Systems, U100), 4mM ATP and 1mM DTT in 20mM MOPS, 100 mM KCl, 
5 mM MgCl2, pH 7.2. Reactions were carried out at 37°C for 2hr, unless 
otherwise indicated, and stopped by boiling in 2x Laemmli loading buffer 
for analysis by immunoblotting. 
Pulldown Assays. Purified ubiquibodies and control proteins were 
conjugated to HisPurTM Ni-NTA Resin (Thermo, 88221) by incubated 
300μg protein with 1mL resin slurry for 30min at 4°C with end-over-end 
rotation. HEK293T cell lysate was prepared by harvesting cells in PBS, 
pelleting at 8000×g for 5min, and freezing at -20°C. Thawed pellets were 
lysed in NP40 lysis buffer (150mM NaCl, 1% Nonidet P-40, 50mM 
TrisHCl, pH 7.4) by pipetting and mixing at 4°C for 30min. Soluble 
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fractions were obtained by centrifugation of lysed cells at 18,000×g at 4°C 
for 20min. Prepared resin was incubated with 10μL lysate at 4°C 
overnight. Resin was washed with buffer (PBS, 25mM imidazole, pH 7.4), 
and proteins were eluted with buffer (PBS, 250mM imidazole, pH7.4). 
Samples were boiled with 2×Laemelli loading buffer and analyzed by 
immunoblot.  
Cell culture, transfection, and lysate preparation. HEK293T 
cells were obtained from ATCC and cultured in standard medium at 37°C 
with 5% CO2. HEK293T cells were cultured in DMEM with 10% heat 
inactivated FBS and 1% antibiotic-antimycotic (Cellgro). Cells were 
transfected in 6-well dishes at 60-80% confluency with 2μg total plasmid 
DNA using empty pcDNA3 plasmid to balance all transfections. 
jetPRIME® transfection (Polyplus Transfection) was performed according 
to manufacturer’s instructions using a 1:2 ratio of jetPRIME® to DNA 
(w:v) and at 4hr post-transfection the growth media was refreshed. At 
24hr post-transfection, cells were harvested by scraping in PBS and 
frozen at -20°C until analyzed by immunoblotting. Thawed pellets were 
lysed in NP40 lysis buffer (150mM NaCl, 1% Nonidet P-40 and 50mM 
TrisHCl, pH 7.4) by pipetting and mixing at 4°C for 30min. Soluble 
fractions were obtained by centrifugation of lysed cells at 18,000xg at 4°C 
for 20min. Samples were boiled in 2x Laemmli sample buffer for analysis 
by immunoblotting and were normalized using a detergent compatible 
total protein assay (Bio-Rad) such that 10μg total protein was loaded. 
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Mass spectrometry analysis. In preparation, ubiquitination 
assays were performed as above. Reactions were resolved by SDS-PAGE 
and stained with Coomassie R250 prior to gel excision. The products of 
each reaction were submitted to the Cornell Biotechnology Resource 
Center Services Proteomics and Mass Spectrometry Facility for detection 
of ubiquitination events. Briefly, the protein bands were cut from an SDS-
PAGE gel and cut into ~1mm cubes. The gel bands were washed in 200µL 
DI water for 5min, followed by 200µL 100mM ammonium bicarbonate 
(ambic)/acetonitrile (ACN) (1:1) for 10min and finally 200µL ACN for 
5min. The acetonitrile was discarded and the gel bands were dried in a 
speed-vac for 10min. The gel pieces were rehydrated with 70µL of 10mM 
DTT in 100mM ambic and incubated for 1hr at 56°C. The samples were 
allowed to cool to room temperature, after which 100µL of 55mM 
iodoacetamide in 100mM ambic was added and the samples were 
incubated at room temp in the dark for 60min. Following incubation, the 
gel slices were again washed as described above. The gel slices were dried 
and rehydrated with 50µL trypsin at 50 ng/µL in 45mM ambic, 10% ACN 
on ice for 30 min. The gel pieces were covered with an additional 25µL of 
45mM ambic, 10% ACN and incubated at 37°C for 19hr. The digested 
peptides were extracted twice with 70µl of 50% ACN, 5% formic acid (FA) 
(vortexed 30min, sonicated 10min) and once with 70µl of 90% ACN, 5% 
FA. Extracts from each sample were combined and lyophilized. The 
lyophilized in-gel tryptic digest samples were reconstituted in 20µL of 
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nanopure water with 0.5% FA for nanoLC-ESI-MS/MS analysis, which 
was carried out by a LTQ-Orbitrap Velos mass spectrometer (Thermo-
Fisher Scientific) equipped with a CorConneX nano ion source device 
(CorSolutions LLC). The Orbitrap was interfaced with a nano HPLC 
carried out by an UltiMate3000 UPLC system (Dionex). The gel extracted 
peptide samples (2-4 µL) were injected onto a PepMap C18 trap column-
nano Viper (5µm, 100µm × 2cm, Thermo Dionex) at 20µL/min flow rate 
for on-line desalting and then separated on a PepMap C18 RP nano 
column (3µm, 75µm x 15cm, Thermo Dionex) which was installed in the 
“Plug and Play” device with a 10-µm spray at Cornell University Library 
on May 30, 2016 http://www.jbc.org/ Downloaded from Selective Protein 
Knockout Using Engineered Ubiquibodies 5 emitter (NewObjective). The 
peptides were then eluted with a 90min gradient of 5% to 38% ACN in 
0.1% FA at a flow rate of 300nL/min. The Orbitrap Velos was operated in 
positive ion mode with nano spray voltage set at 1.5kV and source 
temperature at 275°C. Internal calibration was performed with the 
background ion signal at m/z 445.120025 as the lock mass. The 
instrument was operated in parallel data-dependent acquisition (DDA) 
mode using FT mass analyzer for one survey MS scan for precursor ions 
followed by MS/MS scans on top 7 highest intensity peaks with multiple 
charged ions above a threshold ion count of 7500 in both LTQ mass 
analyzer and HCD-based FT mass analyzer at 7,500 resolution. Dynamic 
exclusion parameters were set at repeat count 1 with a 15sec repeat 
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duration, exclusion list size of 500, 30sec exclusion duration, and ±10 
ppm exclusion mass width. HCD parameters were set at the following 
values: isolation width 2.0m/z, normalized collision energy 35%, 
activation Q at 0.25, and activation time 0.1msec. All data were acquired 
using Xcalibur 2.1 operation software (Thermo-Fisher Scientific). All MS 
and MS/MS raw spectra were processed and searched using Proteome 
Discoverer 1.3 (PD1.3, Thermo-Fisher Scientific) against databases 
downloaded from NCBI-nr database. The database search was performed 
with two-missed cleavage site by trypsin allowed. The peptide tolerance 
was set to 10 ppm and MS/MS tolerance was set to 0.8Da for CID and 
0.05Da for HCD. A fixed carbamidomethyl modification of cysteine, 
variable modifications on methionine oxidation, and ubiquitin 
modification of lysine were set. The peptides with low confidence score 
(with Xcorr score <2 for doubly charged ion and <2.7 for triply-charged 
ion) defined by PD1.3 were filtered out and the remaining peptides were 
considered for the peptide identification with possible ubiquitination 
determinations. All MS/MS spectra for possibly identified ubiquitination 
peptides from initial database searching were manually inspected and 
validated using both PD1.3 and Xcalibur 2.1 software. 
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CHAPTER 3 
THE E3 CATALYTIC DOMAIN 
 
Introduction 
The second requirement of a ubiquibody is E3 catalytic activity. 
E3 catalysis results in transfer of a charged ubiquitin to an 
acceptor lysine on a substrate protein. Two distinct mechanisms for this 
transfer have been identified, though an intermediate mechanism can be 
found in a small subfamily of E3s [57]. In order to design synthetic 
enzymes with the same catalytic capability as natural E3s, we have 
focused on hijacking existing catalytic domains that behave modularly 
within the enzyme as a whole.  
 
 
Figure 3.1: Types of E3 ubiquitin ligase.  
E3 ubiquitin ligases can be sorted based on their catalytic mechanism, which usually 
stems from a conserved characteristic domain (i.e. HECT, RING, or RBR).  
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Classification of E3s based catalytic mechanism results in three 
families of enzyme: HECT, RING, and RBR (Figure 3.1).  
The homologous to E6AP-C terminus (HECT) family is one of the 
smaller families of E3 ligase in the human genome, with a respectable 28 
unique members. HECT E3s are characterized by incredibly diverse N-
terminal regions, which for the 28 enzymes are divided into three 
subfamilies, and highly conserved C-terminal domains, for which the 
family is named  [58, 59]. The C-terminal HECT domain is composed of 
two subdomains, N-lobe and C-lobe, that coordinate the transient 
conjugation of ubiquitin to a catalytic cysteine residue in the C-lobe [60]. 
The HECT domain—if not the entire E3—must interact with E2 and target 
sequentially, due to competition for access to the active cysteine site [61]. 
Unlike other E3 families where the E2 plays a critical role in product 
formation, HECT E3s themselves are responsible for the selection of 
acceptor lysine and subsequent poly-ubiquitin chain linkages [62].  
The largest superfamily of E3s, with upwards of 600 known 
complexes in humans, is the really interesting new gene (RING) and 
RING-like E3s [57]. These ligases are often multi-subunit, large 
complexes with a variety of adaptors. Unlike HECT E3s, RING E3s do not 
contain a catalytic cysteine, and instead bring substrate proteins into 
direct proximity of the charged ubiquitin on the E2 [63]. This means that 
both substrate and charged E2 must be simultaneously bound for 
successful catalysis. While many RING E3s are multi-subunit, such as 
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Cullin-RING ligases or the anaphase promoting complex, a small sub-
family of RING-like E3s, the U-box E3s, function as monomers or 
homodimers. The first generation of ubiquibodies was made using U-box 
E3 catalytic domains [15]; the features and functional parameters of this 
domain will comprise the majority of this report.  
A final family of E3 ubiquitin ligase, RING-between-RING (RBR) 
E3s, have a catalytic mechanism somewhere between HECT and RING 
E3s [57]. The characteristic structure of an RBR E3 is two RING domains 
(R1 and R2) separated by an inbetween ring (IBR) domain [64]. Like HECT 
E3s, RBR E3s transfer ubiquitin to substrate proteins via a two-step 
mechanism, transiently conjugating the charged ubiquitin to a catalytic 
cysteine in the R2 domain, but like RING E3s, require zinc coordination 
to create a platform for E2 binding. Like HECT E3s and U-box E3s, RBR 
E3s tend to function as monomers or homodimers [57].  
The monomeric nature of HECT, U-box, and RBR E3s, combined 
with well-defined consensus catalytic domains, make these types of E3 
attractive for synthetic E3 design. While HECT and RBR E3s would allow 
stricter control over ubiquitination homogeneity, due to the lack of E2-
independent poly-ubiquitin chain formation, U-box E3s offer the 
opportunity for tunable poly-ubiquitination, determined by the subset of 
E2 enzyme interactions.  
The original purpose of ubiquibodies was proteasome-mediated 
silencing of selectable target proteins. This required ubiquibodies derived 
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from a U-box E3 to form catalytically active complexes by binding both 
E2 and target proteins, and to abide by the ubiquitin code [42, 43], 
forming lysine 11 (K11) and/or lysine 48 (K48) poly-ubiquitin linkages—
the canonical linkages recognized by the proteasome. In this work, 
investigation into oligomeric state of ubiquibodies in solution has helped 
elucidate the important features required for productive catalytic activity. 
Because chain specificity is derived from the E2 in U-box catalyzed 
ubiquitination, the subset of human E2 interacting partners of U-box-
based ubiquibodies has been determined. And further investigation into 
the types of poly-ubiquitin chain linkages has confirmed that 
ubiquibodies favor proteasome-targeting linkages in the presence of one 
of their cognate E2s. Finally, alternatives to the U-box scaffold have been 
designed and await testing.  
 
Results 
Rational design of a U-box-based ubiquibody. 
Most U-box E3s follow a similar organization, with an N-terminal 
substrate binding domain, followed by a linker domain of varying 
purpose, and ending with the catalytic U-box domain [65]. Ubiquibodies 
as synthetic U-box-containing E3s, derive their catalytic activity from the 
C-terminus of carboxy-Hsc70 interacting protein (CHIP) (Figure 3.2). 
CHIP is a naturally occurring human E3, that functions as a homodimer 
to mediate the proteolysis of heat-shock and misfolded proteins [66, 67].  
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Figure 3.2: Rational design of U-box driven ubiquibodies.  
(a) Crystal structure of the C-terminal domains of dimerized CHIP. Coiled-coil domains 
(blue) adopts different conformations in each monomer; U-box domains (green) are 
positioned near to each other. PDB ID: 2CL2 [66]. Schematic was generated using 
PyMol software. (b) Cartoon representation of dimerized ubiquibodies. DPS (orange) 
orient asymmetrically due to asymmetry in the coiled-coil domains (blue), resulting in 
blockage of one of the E2 binding sites in the U-box domains (green). Adapted from 
Qian et al. [41]; schematic was generated using Illustrator software. (c) Cartoon of the 
organization of wild type CHIP and CHIP-derived ubiquibodies. Adapted from Portnoff 
et al. [15]. 
 
The dimerization of the CHIP, via its coiled-coil domain, is essential 
for U-box function [41]. Ubiquitination occurs when one subunit of the 
CHIP homodimer interacts with a charged E2 ubiquitin conjugating 
enzyme, via its U-box domain, and a substrate protein via the TPR 
domain of the second subunit (Figure 3.2b). The CHIP homodimer is 
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asymmetric, such that only one E2 binding site is accessible at a time, 
due to blocking of the second site by the second TPR domain as a result 
of a secondary conformation of the coiled-coil region. Because the TPR 
domain is known to be important for the U-box catalytic mechanism, 
ubiquibodies that derive their catalytic activity from CHIP’s U-box while 
replacing the TPR domain with a DBP must be able to either mimic or 
work around this requirement (see Chapter 2).  
Ubiquibodies were designed by fusion of DBPs to the C-terminus 
of CHIP (CHIPΔTPR) via a short, flexible linker (Figure 3.2c). The design 
included the coiled-coil domain, and thus the predicted mechanism of 
ubiquibody catalysis would also depend on dimerization. To determine 
the oligomeric state adopted by ubiquibodies, size exclusion 
chromatography (SEC) was performed (Figure 3.3a). Wild type CHIP 
eluted at volumes expected of a trimer, or a dimer with a large water shell; 
CHIP was prone to aggregation even at ten-fold lower concentrations, 
which may correspond to its native ability to recognize and bind 
misfolded proteins. Ubiquibodies eluted homogenously at volumes 
expected of a tetrameric complex, suggesting the soluble forms could be 
comprised of either a tetramer or dimer of dimers. Unlike CHIP, 
ubiquibodies did not show the same tendency towards aggregation, 
indicating that this property is likely caused by native TPR activity. 
Comparatively, MBP, a known small monomeric protein, eluted at 
volumes expected of a monomer (Table 3.1). These results suggest that 
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ubiquibodies multimerize, forming dimers or larger complexes. To further 
investigate the quaternary structure of ubiquibodies in solution, blue 
native poly-acrylamide gel electrophoresis (BN-PAGE) was performed 
using purified ubiquibodies (Figure 3.3b). The unfused DBP, DARPin 
EpE89, ran at molecular weights corresponding to theoretical monomers 
and dimers, though detection of proteins of this size was near the lower 
limit of this assay. Conversely, CHIPΔTPR ran at multiple molecular 
weights higher than expected for either a monomer or dimer, indicating 
that this domain alone is sufficient for oligomerization. Bands of varying 
size were detected for CHIPΔTPR, suggesting that this protein may also 
be prone to aggregation. Full length ubiquibodies ran at the expected 
molecular weight of a dimer, and did not show the same tendency for 
multiple oligermized states.  Taken together, these data suggest that 
ubiquibodies dimerize in solution, similar to wild-type CHIP. The C-
terminal CHIPΔTPR region is responsible for this oligomerization, and 
potentially facilitates the formation of larger complexes.   
 
Table 3.4: Oligomeric state of ubiquibodies 
 
Theoretical 
Monomeric MW 
(kDa) 
Elution Vol. 
(mL) 
Experimental MW 
(kDa) 
Max. 
Oligomeric 
State 
CHIP 37.13 12.03 136.73 3.7 
E40-uAb 40.56 12.27 194.92 4.8 
pE59-uAb 36.98 12.45 179.02 4.8 
EpE89-uAb 37.01 12.37 185.92 5.0 
MBP 43.39 14.80 58.93 1.4 
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Figure 3.3: Oligomerization of U-box ubiquibodies.  
(a) Size exclusion chromatography (SEC). Purified proteins were analyzed by SEC 
using a HiLoad Superdex 200 column. Elution profiles of three ubiquibodies are 
compared relative to wild type CHIP, which aggregated at high concentration, and 
MBP. (b) BN-PAGE of ubiquibodies. Immunoblot of purified ubiquibody and control 
proteins following BN-PAGE detected with the indicated antibody. [51] 
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In the course of this project, crystallization of the R4-uAb, OFF7-
uAb, and EpE89-uAb was attempted, though no diffractable crystals 
formed under any of the tested conditions.  
Functional characterization of U-box ubiquibodies 
To demonstrate that U-box fusion results in functional synthetic 
E3 ubiquitin ligases, in vitro ubiquitination assays were performed 
(Figure 3.4). Incubation with components of the UPP (E1, E2, ubiquitin, 
and ATP) and EpE89-uAb resulted in the formation of higher molecular 
weight species of ERK2-GST. The appearance of these species correlated 
with the appearance of high molecular weight ubiquitin species, 
indicating that EpE89-uAb ubiquitinated ERK2-GST in a time dependent 
manner (Figure 3.4a). To confirm that each component of the pathway 
was necessary for ubiquitination of ERK2-GST, assays lacking one of 
each of the UPP proteins (or ATP) were performed (Figure 3.4b). Only 
when all components, including the full EpE89-uAb, were present was 
ubiquitination of ERK2-GST observed. Neither the binding domain, 
EpE89, nor catalytic domain, CHIPΔTPR, alone resulted in ubiquitination 
of ERK2-GST. Importantly, the presence of a catalytic domain, regardless 
of DPB presence or specificity, led to the formation of high molecular 
weight species of ubiquitin; similar molecular weight species were 
observed in detection of the ubiquibody, indicating that auto-
ubiquitination is a prominent side reaction in this system. Auto-
ubiquitination was significantly reduced in the presence of a cognate 
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target, indicating that the two reactions are in competition. Overall, the 
U-box domain has been confirmed to be an effective supplier of E3 
catalytic activity to ubiquibodies against non-native targets.  
 
 
Figure 3.4: In vitro ubiquitination assay with U-box-containing ubiquibodies.  
(a) Time dependent ubiquitination of ERK2-GST. At the indicated time points, samples 
were removed and analyzed by immunoblot with the indicated antibodies. (b) UPP 
component necessity for catalytic activity of U-box-containing ubiquibodies. Reactions 
with the indicated components were incubated for 2hr, then analyzed by immunoblot. 
[51] 
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In order to determine the type of ubiquitin linkages formed by 
ubiquibodies, the above reactions were tested for presence of K48, K63 
and K27 ubiquitin-ubiquitin linkages (Figure 3.5a). (Note that antibodies 
for the detection of K6, K11, K29, and K33 linkages were unavailable at 
the time of this project.) In the presence of a U-box catalytic domain, high 
molecular weight species of K48 and K63 linkages were detected, while 
no such K27 species were observed. While comparative levels of K48 
linkages were observed regardless of the presence of target protein, the 
level K63 linkages decreased when auto-ubiquitination was the only 
catalyzable reaction. This suggests that K63 linkage formation is 
benefitted by the presence of target and that this type of poly-
ubiquitination is more likely to be found on target substrates. Ubiquibody 
and target would be expected have similar levels of K48-linked 
ubiquitination. 
All ubiquitination reactions reported up to this point were 
performed with the E2 enzyme family member Ube2D1 (a.k.a. UbcH5A), 
which was previously shown to interact with wild type CHIP [68]. To 
further characterize the poly-ubiquitination profile of ubiquibodies in the 
presence of Ube2D1, reaction products (60-250kDa) were analyzed by 
mass spectrometry. From samples containing EpE89-uAb and Ube2D1, 
ubiquitination on four ubiquitin lysine residues, K6, K11, K48, and K63, 
were found (Figure 3.5b and c). The relative abundance of these linkages 
was estimated across six independent experiments, three with ERK2 as 
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the target protein, and three with pERK2 as the target protein. K48 and 
K63 linkages were the most commonly found, while K6 linkages were 
least often found. The majority of ubiquibody poly-ubiquitination 
consisted of proteasome-specific linkages (K11 and K48).  
 
 
Figure 3.5: Poly-ubiquitin linkage profile of EpE89-uAb with UbcH5α.  
(a) Formation of poly-ubiquitin chains by ubiquibodies. Reactions were halted after 
2hrs and analyzed by immunoblot with the indicated antibodies. (b) Cartoon 
representation of lysine linkages mapped to the ubiquitin crystal structure. Ubiquitin 
(white ribbon) contains seven lysine residues (spheres); the relative ubiquitination 
levels of each lysine by the EpE89-uAb are represented in shadings of blue. PDB ID: 
1UBQ [68]. Schematic was generated using PyMol Software. (c) Occupancy rate of –GG 
modification of ubiquitin by EpE89-uAb. Bars were generated by normalizing modified 
residue coverage with total residue coverage and averaging across six experiments, 
three with ERK2 and three with pERK2. [51] 
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To ensure that this ubiquitination profile was not a result of DBP 
or linker effects, similar experiments were performed while varying either 
the DBP or the linker (Figure 3.6). When the EpE89 was exchanged for 
E40 or pE59, no significant differences in the formation of poly-
ubiquitination K6, K11, K48, or K63 linkages were observed. However, 
both E40-uAb and pE59-uAb demonstrated the ability to catalyze K27 
linkages, abet at extremely low levels. Thus, DARPin DBPs do not appear 
to greatly affect the types of poly-ubiquitin chains formed by the U-box. 
When the 5AA linker was exchanged for one of four longer linkers (see 
Chapter 4), a significant decrease in K63 poly-ubiquitin linkages was 
observed, though the relative levels of K6, K11, and K48 linkages 
remained constant. No ubiquitination of novel residues was observed by 
ubiquibodies of varying linker composition. This suggests that linker 
length and flexibility plays at least a minimal role in the determination of 
lysine linkages, with the possibility of reducing non-proteasomal K63 
linkages with varying linker composition. Overall however, the primary 
determination of poly-ubiquitination appears to be linked to the U-
box/E2 combination, and remains mostly undisturbed by changes to 
other domains of the ubiquibody.  
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Figure 3.6: Effect of DBP and linker domains on poly-ubiquitin chain type.  
(a) Occupancy rate of ubiquitination on ubiquitin lysines by different ubiquibodies. (b) 
Occupancy rate of ubiquitination on ubiquitin lysines by ubiquibodies of varied linker 
length. Bars were generated by normalizing modified residue coverage with total 
residue coverage and averaging across (a) six independent experiments, three with 
ERK2 as the target and three with pERK2 as the target, or (b) across two independent 
experiments, with ERK2 as the target. [51]  
 
To determine which other E2s ubiquibodies might interact with in 
cells, in vitro ubiquitination assays using a panel of human E2s 
(Ubiquigent) were performed. Forty-one E2s are encoded in the human 
genome [69]; a subset of thirty-two human E2s were used to screen the 
EpE89-uAb for catalytic activity (Appendix B). The ubiquibody catalyzed 
the formation of high molecular weight ubiquitin species with twenty-two 
of these E2s (Figure 3.7 and Table 3.2), and of these, only nine 
corresponded to shifts of ERK2-GST to higher molecular weights, 
indicating that target ubiquitination by U-box E3s is mediated by a small 
subset of the E2s available in mammalian cells. Ube2D1, Ube2D2, and 
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Ube2D3 (all members of the UbcH5 E2 family), were the only E2s which 
catalyzed both ubiquitination of ERK2-GST and K48 poly-ubiquitin 
chains, indicating that proteasomal targeting by ubiquibodies in cells 
would likely be mediated by some combination of these E2s. (Other E2s 
that preferentially form K11 linkages could also contribute to 
proteasomal targeting.) Notably, many of the E2s that resulted in poly-
ubiquitin species did not correspond to either ERK2-GST ubiquitination 
or auto-ubiquitination. This suggests that U-box fusions are capable of 
forming free ubiquitin chains, in some cases dozens of ubiquitin residues 
long. A subset of E2s, Ube2E2, Ube2E3, Ube2F and Ube2W, catalyzed 
mono-ubiquitination of ERK2-GST. In cells, this type of event often acts 
as a primer for downstream poly-ubiquitination by other E2s that are 
capable of ubiquitin chain extension [70, 71]. To fully elucidate the E2s 
which could function as ERK-Ub chain extenders, reactions containing 
mono-ubiquitin primed ERK should be performed. The only instance of 
K27 formation was with Ube2E1, but did not correspond to modification 
of either the target or ubiquibody. Should other linkage-specific 
antibodies become available, it will be interesting to determine the full 
profile of poly-ubiquitin chains formed by ubiquibodies against most of 
the E2 conjugating enzymes found in humans.  
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Figure 3.7: E2 scan of EpE89-uAb ubiquitination activity.  
Immunoblot analysis of in vitro ubiquitination activity of the EpE89-uAb in the 
presence of different E2s (full list found in Appendix B) with the indicated antibodies. 
*Indicates different exposure of blots. [51] 
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Table 3.5: E2 interacting partners of EpE89-uAb. 
La
ne
 
E2 Alternate Name Ub
X-T
ar
ge
t 
Ub
-u
Ab
 
Ub
1-T
ar
ge
t 
K2
7 
K4
8 
K6
3 
4 Ube2D1 UbcH5A       
5 Ube2D2 UbcH5B       
6 Ube2D3 UbcH5C       
7 Ube2D4 UbcH5D       
8 Ube2E1 UbcH6       
9 Ube2E2 UbcH8       
10 Ube2E3 UbcH9       
11 Ube2F NCE2       
12 Ube2G1 Ubc7       
13 Ube2G2 Ubc7       
14 Ube2H UbcH2       
15 Ube2I Ubc9       
16 6His-Ube2J1 NCUBE1       
17 Ube2J2 NCUBE2       
18 Ube2K Ubc1       
23 Ube2N/Ube2V1 Ubc13/Uev1A       
24 Ube2N/Ube2V2 Ubc13/Mms2       
27 Ube2R1 CDC34       
28 Ube2R2 CDC34B       
29 Ube2S E2-EPF       
30 Ube2T HSPC150       
33 6His-Ube2W Ubc16       
PC Ube2D1 UbcH5A       
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As a final curiosity concerning the E2:uAb:target active catalytic 
complex, a brief investigation into the kinetics of the reaction was made 
(Figure 3.8). Simultaneously increasing E2 concentration and 
decreasing target concentration shifted reactions towards more extensive 
ubiquitination of ERK2-GST, as seen by the reduction of the unmodified 
ERK2-GST bands and increase of poly-ubiquitin conjugate smears in 
lanes 2 and 4. At standard reaction concentrations, ubiquitin is in great 
excess to the other reaction components; however, a two-fold reduction 
of available ubiquitin drastically reduced both ERK2-GST ubiquitination 
and ubiquitination in general. The effect of decreased ERK2-GST 
ubiquitination was ameliorated by the above changes to E2 and ERK2-
GST concentrations, indicating that the reduction of poly-ubiquitin 
species in lane 3 was not the result of reducing ubiquitin concentrations 
to the level of limiting reagent, but rather, more complex interactions of 
between charged E2, target, and ubiquibody. Reduction of ubiquibody 
concentration similarly reduced global ubiquitination levels. These 
results suggest that ubiquitination is a highly sensitive to all components 
found in the catalytically active complex. (Because the ATP consumption 
of this reaction occurs several steps before transfer of ubiquitin to target 
lysine, common methods for determining rates of reaction based on ATP-
depletion are not applicable.) Further investigations into the kinetics of 
ubiquitination could benefit from empirically trained computational 
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modeling, and should eventually be tuned to account for the 
concentrations of each of these reactants in vivo.  
 
 
Figure 3.8: Effects of E2 and target on ubiquibody-mediated ubiquitination. 
Immunoblots of in vitro ubiquitination assays halted after 2hr, varying the relative 
concentrations of E2, target, ubiquitin, and uAb. The base concentrations for each 
reaction are shown above lane 1. In subsequent lanes an up-arrow represents a two-
fold increase in component concentration and a down-arrow, a two-fold decrease in 
component concentration.  
 
Rational design of alternative E3 Scaffolds 
The first generation, as well as the ubiquibodies reported here, 
have relied on a single catalytic domain type. However, the wide diversity 
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of naturally occurring E3s suggests potential for both optimization and 
diversification of the ubiquibody scaffold. Towards this end, rational 
design of two different E3 ubiquitin ligase catalytic domains for 
incorporation into ubiquibodies are reported here. Test constructs of 
these ubiquibodies, using ERK DARPins as the DBPs, have been 
generated and await preliminary testing.  
HECT and HECT-like E3s remove the variability of E2-dependent 
ubiquitin linkages and are therefore attractive as simplified silencing 
agents. One such ligase, Smurf2, is a 747 amino acid protein, containing 
an N-terminal membrane interacting domain and the canonical HECT C-
terminal domain starting at residue 393 [72]; the full sequence, with 
overlaid domains, is shown in Appendix A.7. The HECT domain alone 
has been shown to be sufficient for thioester conjugation [73]; thus, in 
designing Smurf2 based ubiquibodies (uAbSmurf2), residues Y368-E478 
(Smurf2HECT) were deemed essential. Because flexibility has also been 
shown to be critical for HECT E3 activity, the unstructured linker 
between the last WW domain and the HECT domain was included, 
resulting in a 356 amino acid HECT catalytic domain (Smurf2CTD) 
(Figure 3.9)  
72 
 
 
Figure 3.9: Rational design of HECT-based ubiquibodies.  
(a) Crystal structure of the HECT domain of human Smurf2. Smurf2 (green) in its T-
shape conformation; catalytic cysteine (red) is surface exposed. PDB ID: 1ZVD [74]. (b) 
Cartoon map of domain organization in wild type Smurf2 and uAbSmurf2.  
 
Alternatively, RBR E3 ubiquitin ligases exhibit similarities to both 
HECT and RING ubiquitin ligases, making them interesting sources of E3 
catalytic activity. Auto-regulatory mechanisms for this family are of 
particular interest for potential RBR-ubiquibodies.  
Parkin, one of the most famous RBR E3s because of its prominent 
role in Parkinson’s disease, is structurally well-characterized, containing 
Ubl and R0 domains, in addition to the canonical RBR catalytic core [75]. 
Parkin exhibits both HECT-like and RING-like catalytic activities, 
dependent on the R1, IBR and R2 domains. The Ubl domain is important 
for proteome-co-localization of Parkin, and the R0 domain is thought to 
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regulate Parkin activation by interaction with the R2 domain, inhibiting 
its catalytic cysteine. C431, in the inactive state.  
To design ubiquibodies that hijack Parkin’s catalytic properties, 
truncations of the N-terminal domain up to residue 217 were made 
(Figure 3.10). This resulted in a 249 amino acid C-terminal domain of 
Parkin (ParkinCTD), that contained intact sequences of the R1, IRB, and 
R2 domains. Direct fusion of the DBP was used, generating a family of 
ubiquibodies, designated uAbParkin. Although this design did not include 
it, the Ubl domain could be incorporated in later iterations of uAbParkin, 
to aid in co-localization with the proteasome and better facilitate targeted 
protein silencing.  
 
 
Figure 3.10: Rational design of RBR-based ubiquibodies.  
(a) Crystal structure of the RBR domain of human Parkin. Parkin (green) adopts an 
extended conformation; catalytic cysteine (red) is surface exposed. PDB ID: 5C1Z [75]. 
(b) Cartoon map of domain organization in wild type Parkin and uAbParkin2.  
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As of this report, uAbSmurf2 and uAbParkin constructs have been 
generated (using the panel of ERK-specific DARPins as DBPs). Similar in 
vitro and in vivo characterization as outlined here for CHIP-based 
ubiquibodies could yield novel and exciting advancements to the control 
over the ubiquibody technology.  
 
Discussion 
In this study, the ubiquitination activity of U-box-containing 
ubiquibodies has been further elucidated.   
For a U-box derived ubiquibody, dimerization is simultaneously 
interestingly intrinsic to ubiquibody function and frustratingly 
complicating to an already complex system. The fact that ubiquibodies 
behave in a manner similar to wild type CHIP is foretelling of their ability 
to integrate into the UPP without additional chaperones. Notably, 
dimerization introduces a second target binding site (see Chapter 5), that 
could lead to non-catalytically active ubiquibody:target complexes. This 
possibility is supported by the increase in ubiquitination seen when the 
E2 concentrations are increased relative to the target, suggesting that 
E2s must outcompete targets binding to the DBP to access the available 
U-box site in the same half of the dimer.   
Ubiquitination profiles for ubiquibodies with the E2 Ube2DE1 have 
been determined by immunoblot and mass spectrometry. The prevalence 
of K11 and K48 poly-ubiquitin linkages offer explanation for successful 
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silencing of proteins observed in vivo. The E2 interacting partners of 
CHIPΔTPR fusion proteins have been determined, and the subset of E2s 
that lead to K48 linked chains have been found. One possibility for 
optimizing protein silencing by CHIP-derived ubiquibodies is directed 
evolution of the U-box domain for selective interaction with the subset of 
E2s that generate the preferred ubiquitin chains. Alternatively, as K63 
linkages may be correlated to the flexibility of the ubiquibody, as seen by 
their reduction with more flexible ubiquibodies, linker optimization may 
aid in the preferential formation of proteasome-specific poly-ubiquitin 
linkages.  
While ubiquibodies are no longer unique as a technology for 
synthetic E3-mediated protein silencing by the proteasome, they the 
older of the two platforms that utilize a U-box scaffold [15, 76], both 
derived from CHIP. Other groups have reported ubiquibody-like proteins 
that contain catalytic analogs to CHIPΔTPR, including subunits of the 
Cullin RING E3 complex [77, 78]. To date, no ubiquibody-like technology 
based on a mammalian HECT E3 has been published. However, 
coinciding with the progression of this project, another E3 catalytic 
domain, derived from bacterial IpaH9.8 [79], was introduced into 
ubiquibodies by another member of the DeLisa group. The NEL domain 
of IpaH9.8 has been proven to be a powerful mediator of targeted protein 
silencing, and many of the future generations of ubiquibodies will be built 
from it.   
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Methods 
Genes and plasmid construction. Plasmids were constructed as 
described in Chapter 2 and Chapter 4. Human Smurf2 and Parkin genes 
were obtained from Addgene (Plasmid #13678: pRK-Myc-Smurf2 and 
Plasmid #17613: pRK5-HA-Parkin).  
Protein expression and purification. All purified proteins were 
obtained from cultures of E. coli BL21(DE3) cells grown in of Luria-
Bertani (LB) medium. Expression was induced with 0.1mM IPTG when 
the culture density (Abs600) reached 0.6-0.8 and proceeded at 30°C for 
6hr, after which cells were harvested by centrifugation at 4,000×g for 20 
min at 4°C. The resulting pellets were stored at -80°C overnight. Thawed 
pellets were resuspended in 15mL buffer (PBS, 10mM imidazole, pH 7.4) 
and lysed with a high-pressure homogenizer (Avestin EmulsiFlex C5). 
Lysates were cleared by centrifugation at 20,000×g for 20min at 4°C. 
His6-tagged proteins were subjected to gravity Ni2+-affinity purification 
HisPurTM Ni-NTA Resin (Thermo 88221) following manufacturer’s 
protocols. Samples were desalted into buffer (PBS, pH 7.4) using PD 10 
Desalting Columns (GE Healthcare 17-0851-01) following 
manufacturer’s protocols. Samples were stored at 4°C for up to two weeks 
or diluted to 25% glycerol and stored at -80°C indefinitely. 
Protein analysis. SDS-PAGE and immunoblotting of proteins was 
performed according to standard procedures. The following primary 
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antibodies were utilized for immunoblotting: rabbit anti-ERK (Cell 
Signaling Technology, 9102), mouse anti-ubiquitin (Millipore, P4D1-A11), 
rabbit anti-6x-His-HRP (Abcam, ab1187), rabbit anti-Flag-HRP (Abcam, 
ab49763), rabbit anti-ubiquitin: linkage specific K27 (Abcam, ab181537 
rabbit anti-ubiquitin: linkage specific K48 (Abcam, ab179434) rabbit 
anti-ubiquitin: linkage specific K63 (Abcam, ab140601). Secondary 
antibodies goat anti-rabbit IgG (H+L) and anti-mouse IgG (H+L) with HRP 
conjugation (Promega) were utilized as needed. 
Size exclusion chromatography. SEC experiments were 
performed on an ÅKTA FPLC using a HiLoad Superdex200 column (GE 
Healthcare) according to manufacturer protocols. A standard curve for 
molecular weight was generated using Gel Filtration Molecular Weight 
Markers (blue dextran, cytochrome c, carbonic anhydrase, alcohol 
dehydrogenase, and β-amylate) (Sigma). 
Blue native PAGE. Purified ubiquibodies and control proteins were 
diluted to the indicated concentrations with PBS, pH 7.4 and 10× loading 
buffer (0.1% Ponceau S (w/v), 5% glycerol (w/v)). 10μL sample were 
loaded into the lanes of a NativePAGETM 4-16% Bis-Tris (Invitrogen). 
Electrophoresis was performed with anode buffer (25mM imidazole, pH7) 
and 10× cathode buffer (50mM tricine, 7.5mM imidaxole, 0.02mM 
Coomassie blue G-250, pH7) at 4°C for 30min at 100V, then 30min at 
200V. Cathode buffer was exchanged to 1×, and electrophoresis 
continued at 200V for 3hr. Semidry transfer of the gel to PVD-membrane 
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was performed at 80mAmp for 75min. Membrane was destained in buffer 
(25% methanol, 10% acetic acid) for 1hr to overnight. NativeMark ladder 
(Thermo) was marked, and membranes were destained in 100% methanol 
for 5min then analyzed by immunoblot.  
In vitro ubiquitination assays. Unless otherwise indicated, in 
vitro ubiquitination reactions were performed as outlined in Chapter 2.  
Mass spectrometry. Mass spectrometry analysis of ubiquitination 
reaction products was performed as described in Chapter 2.  
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CHAPTER 4 
THE LINKER 
Introduction 
Linkers are naturally of great importance in multi-domain proteins. 
Flexibility is a key attribute, determined by composition and length, as 
linkers must often allow surrounding domains to reposition for catalysis 
or with structural rearrangement [80, 81]. The average linker length in 
natural multi-domain proteins is around 10 residues and favor short or 
α-helical or coil structures [82]. Conversely, synthetic linkers are often 
optimized for solubility and flexibility, with secondary regard for 
secondary structure. scFvs, through treated as a single domain in the 
ubiquibody, actually consist of two domains, a VH and a VL, connected by 
a flexible linker engineered to increase its stability and folding [83]. 
Linkers like these are often rich in small or hydrophilic residues, such as 
glycine and serine, allowing for dramatic degrees of relative rotation of 
the two flanking poly-peptide regions while maintaining high solubility 
[84].  
The initial design of ubiquibodies included a short linker between 
the DBP and the catalytic domain, to maintain flexibility between the first 
DBP, an scFv, and the coiled-coil region of CHIPΔTPR [15]. This inclusion 
was made in response to findings of Qian et al. that showed flexibility 
was critical for catalytic function of CHIP [41]. The first generation of 
ubiquibodies, based on this design, incorporated a five amino acid GS 
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linker, with the express purpose of maintaining the flexibility needed for 
catalytic conformation changes [15]. The full spacing between the 
flanking domains was seven residues, due to genetic incorporation of an 
EcoRI site intended DBP modularity. This restriction site abutted the 
GSGSG sequence, resulting an effective seven amino acid linker 
(EFGSGSG) between the DBP and CHIPΔTPR. In this report, preliminary 
targeted variations to this deceptively simple domain are explored. 
 
Results 
In an effort to further explore linker effects on ubiquibody function, 
a panel of varied linker lengths was designed (Table 4.1). Linkers of 5, 
10, 15, 20, and 134 amino acids were genetically fused between the DBP 
and U-box domains of the ubiquibody scaffold. To maximize flexibility 
and reduce secondary structure effects, the EcoRI site (translated to EF) 
was exchanged for a BamHI (translated to GS). Three of the linkers, 5AA, 
10AA, and 20AA, were modeled after the first generation linker, 
consisting of a GSGSG motif in singlet, duplicate, and quadruplicate 
respectively. The 15AA was derived from a eukaryotic inter-domain 
linker, native to human Rieske; the crystal structure of Rieske shows the 
linker to be unstructured, but important for flexibility between the 
catalytic domain and transmembrane anchor [85]. Unlike the other small 
linkers, the 15AA is not GS rich. The 134AA was taken from the C-
terminal domain of Hsp70, a native interacting partner of CHIP [66]. 
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Natively, this domain functions as both a lid for the substrate binding 
domain of Hsp70 and interacting partner for native CHIP, via the TPR 
domain. Because this α-helical rich domain has been shown to be 
important for ubiquitination of Hsp70/Hsc70 bound substrates [86], a 
direct fusion of this domain to the CHIPΔTPR was made  Theoretically, 
longer flexible linkers should endow ubiquibodies with a larger radius of 
catalytic activity.  
 
Table 4.6: Ubiquibody linker design. 
Designation Sequence 
Length 
(AA) Ref 
5’ BamHI GS 2  
5AA GSGSG 5  
10AA GSGSGGSGSG 10  
15AA TSMTATADVL AMAAA 15 [85] 
20AA GSGSGGSGSG GSGSGGSGSG 20  
134AA 
itndkgrlsk ddidrmvqea eryksedean rdrvaaknal esytynikqt 
vedeklrgki seqdknkild kcqevinwld rnqmaekdey ehkqkelerv 
cnpiisklyq ggpgggsggg gsgasggpti eevd 
134 
[66] 
 
The linker panel derived from EpE89-uAb was checked for soluble 
expression in E. coli (Figure 4.1). All five ubiquibody variants showed 
high levels of full-length expression, as seen by Coomassie staining and 
immunoblot, though the 134AA ubiquibody showed a proclivity for 
degradation in vivo.  
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Figure 4.1: Soluble expression of EpE89-uAb linker panel in E. coli.  
The linker panel of EpE89-uAb expressed well at expected molecular weights of 36.6, 
37.0, 37.4, 37.6, and 51.2 kDa respectively, though 134AA showed a tendency for 
degradation.  
 
To test the ability of the linker panel to ubiquitinate substrate 
proteins, in vitro ubiquitination assays were performed using purified 
components of the UPP and ERK2 (Figure 4.2). Ubiquitination of ERK2-
GST was observed with all five ubiquibodies, though to a lesser extent 
with 134AA EpE89-uAb. Poly-ubiquitin species of high molecular weight 
were observed in all cases as well, though 10AA, 20AA, and 134AA 
ubiquibodies showed stronger ubiquitination. Presumably, the high 
levels of ubiquitination seen by anti-ubiquitin immunoblot for the 134AA 
ubiquibody correspond to increased auto-ubiquitination of the 
ubiquibody itself, rather than the substrate protein. Indeed, the 134AA 
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linker provides fourteen additional lysine residues. Conversely, the 
decrease in overall ubiquitination by the 5AA and 15AA ubiquibodies as 
seen by anti-ubiquitin immunoblot, suggest that auto-ubiquitination is 
decreased relative to the 10AA and 20AA ubiquibodies, while substrate 
ubiquitination is unaffected, as seen by anti-ERK immunoblot. Taken 
together, these results suggest that substrate ubiquitination is better 
facilitated by shorter, flexible linkers, while poly-ubiquitination in general 
is better supported by a combination of increased GS composition and 
longer length.   
 
 
Figure 4.2: In vitro ubiquitination by the EpE89-uAb linker panel.  
Ubiquibodies derived from the EpE89-uAb were incubated with E1, E2, ubiquitin, 
ERK2-GST and ATP for two hours. Shifts to higher molecular weight species of ERK2-
GST were observed with all ubiquibodies, though to a lesser extent with 134AA 
EpE89-uAb. Poly-ubiquitination was seen in all cases, though most strongly with 
10AA, 20AA, and 134AA ubiquibodies. [51] 
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To determine the lysine residues susceptible to ubiquitination by 
the linker panel of the ubiquibodies, the high molecular weight (60-250 
kDa) reaction products of in vitro ubiquitination assays were analyzed by 
mass spectrometry. (The 5AA ubiquibody was excluded from this 
analysis, and the other linker panel members were compared to the 
original EpE89-uAb containing the EFGSGSG linker ubiquitination 
profile).  Surprisingly, the number of ERK lysines modified with ubiquitin 
decreased with increasing linker length (Figure 4.3). Notably, all 
ubiquitination sites were contained within the subset of lysines found to 
be ubiquitinated by the original EpE89-uAb (see Chapter 3). The 15AA 
and 20AA ubiquibodies, despite extreme compositional differences, were 
found to ubiquitinate the same four lysine residues, clustered on the top 
surface of ERK2. The 10AA ubiquibody ubiquitinated the same set of 
lysines as EpE89-uAb, except for K258. The 134AA ubiquibody was 
found to ubiquitinate a single site on ERK2, outside of the C-terminal 
cluster seen with all other ERK-uAbs. The large α-helical structure of this 
linker may block the catalytic domain from the bound substrate, rather 
than allow the U-box domain to expand its access to the surface 
accessible lysines on other faces of ERK2.  
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Figure 4.3: Substrate ubiquitination profiles of the EpE89-uAb linker panel.  
(a) Ubiquitination frequency of ERK2 lysine residues by EpE89-uAb variants. (b) 
Ubiquitination site map on ERK2 crystal structure: backbone (white ribbon), 
unmodified lysine residues (white spheres), lysines ubiquitinated by all linker panel 
ubiquibodies (dark purple), a subset of ubiquibodies (purple), or only the 10AA 
ubiquibody (light purple), lysines not covered by mass spec analysis (grey). Modified 
from PDB ID: 3ZU7 [26]. Schematic was generated using PyMol software. [51] 
 
The pattern of auto-ubiquitination changed with varying linker 
length (Figure 4.4). Compared to the original EpE89-EF-GSGSG-uAb, 
the linker panel showed novel auto-ubiquitination patterns.  For the 
10AA and 15AA ubiquibodies, no auto-ubiquitination was observed by 
mass spectrometry analysis. For the 20AA ubiquibody, a single auto-
ubiquitination site in C-terminal capping region of the DARPin (and found 
in the auto-ubiquitination pattern of the original EpE89-uAb) was 
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identified. The 134AA linker auto-ubiquitinated four sites, K7 and K101 
of DARPin EpE89, and two novel sites, K10 and K55, within the linker 
itself. None of the linker panel ubiquibodies ubiquitinated sites in the U-
box domain. The changes in auto-ubiquitination pattern within the series 
itself suggest that longer linkers allow for more flexible positioning of the 
U-box relative to its DARPin fusion partner, although, comparisons to the 
original construct belie that conclusion. However, the composition of the 
linker, when it includes novel lysine residues, plays an important role in 
the ability of a ubiquibody to auto-ubiquitinate. 
  
 
Figure 4.4: Auto-ubiquitination of linker EpE89-uAb.  
(top) Cartoon diagram of the ubiquibody structure. (bottom) Site map of auto-
ubiquitinated lysines (numbered from start of domain). Sites unique to 134AA linker 
are show in red. Underlined sites were conserved from the original auto-ubiquitination 
pattern by the 134AA uAb (single) or by both the 20AA and 134AA uAbs (double).   
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Discussion 
Linker biology provides an important control point for engineered 
proteins. In its simplest form, the linker simple separates two domains 
in a polypeptide sequence; in more complex forms, the linker can act as 
a switch or important structural landmark within the fully folded protein. 
The linker incorporated into a ubiquibody will play a previously 
underestimated role in the lysine specificity of the E3 catalytic domain.  
In this work, five variants of the first generation linker were 
characterized in vitro. While all led to active, full length constructs, 
differences in ubiquitination preferences became apparent in 
immunoblot results and confirmed by mass spectrometry analysis. 
Conversely to the original hypothesis, increasing linker length 
corresponded to a decrease in the number of accessible target lysine 
residues. While some of this may be attributed to the length, underlying 
structural difference in the linkers may play a role in the different 
ubiquitination profiles observed.  
In regards to auto-ubiquitination, with the exception of the longest 
linker, no novel auto-ubiquitination sites were introduced by varying 
linker length and both new sites in the 134AA linker auto-ubiquitination 
profile were located in the linker itself.  Since auto-ubiquitination is a key 
regulatory feature of E3 ubiquitin ligases, it may benefit ubiquibody 
stability to either prevent, or more tightly control, this modification. 
Within this panel of linker ubiquibodies, no ubiquitination of the 
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CHIPΔTPR domain was found; and only a single residue in this domain 
was ubiquitinated by the original ubiquibody construct. Linkers and 
DBPs lacking lysine residues, or containing K→R mutations, may lead to 
an increase in protein stability in vivo by preventing ubiquibody turnover 
by self-targeting to the proteasome. Additionally, the use more rigid or 
more structured linkers may prevent auto-ubiquitination by steric-
enforced separation of the catalytic and DBP domains.  
The potential of the linker domain is one of the most exiting areas 
of ubiquibody design. Because of its modular nature, more complex 
linkers, such as switches that can temporally regulate E3 activity, or 
localization signals, that could cause the ubiquibody to sub-cellularly 
localize could be incorporated into future generations of ubiquibodies.   
 
Materials and Methods 
Plasmid construction. Linker plasmids of the form pET28a(+)-
NcoI-GS2-X-BamHI-CHIPΔTPR-SalI-Flag-His-TAA-HindIII, where X 
corresponds to each of the linkers in Table 4.1, were obtained by gene 
synthesis (Twist Bioscience). The EpE89 DBP was amplified from 
pET28a(+)-EpE89-uAb, with primers introducing an 5’ NcoI sites and a 
3’ BamHI site; PCR product was double digested (NcoI/BamHI) and 
ligated into linker plasmid backbones.  
Protein expression and purification. Proteins were purified as 
indicated in Chapter 2 and Chapter 3. 
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Protein analysis. SDS-PAGE and immunoblotting of proteins was 
performed according to standard procedures. BioRad Coomassie R-250 
stain was used to visualize proteins in SDS-PAGE (BioRad, Mini-
PROTEAN® TGX). The following primary antibodies were utilized for 
immunoblotting: rabbit anti-ERK (Cell Signaling Technolgy, 9102), 
mouse anti-ubiquitin (Millipore, P4D1-A11), rabbit anti-6x-His-HRP 
(Abcam, ab1187). Secondary antibodies goat anti-rabbit IgG (H+L) and 
anti-mouse IgG (H+L) with HRP conjugation (Promega) were utilized as 
needed.  
Ubiquitination assays. Ubiquitination assays were performed as 
described in Chapter 2 
Mass spectrometry analysis. Mass spectrometry analysis was 
performed as described in Chapter 2.  
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CHAPTER 5 
THE ANATOMY OF A UBIQUIBODY 
Introduction 
Traditional protein silencing has been primarily achieved with the 
use of small molecule inhibitors. These compounds, often the active 
components of therapeutics, can be range greatly in potency and act 
either allosterically or competitively, to prevent native protein function. 
Unfortunately, the proteome has a high level of homology, often leading 
to off-target effects, that are only exacerbated by the fact that drugs must 
work in a one-to-one molar ratio with the proteins they silence. Higher 
concentrations of lead to higher rates of off-target effects. Furthermore, 
not all proteins are ‘druggable’, in that a useful binding cleft, where a 
small molecule could potentially inhibit protein function, does not exist 
[87]. These limitations of small molecules inhibitors necessitate the need 
for specific and enzymatic silencing.  
The term ‘ubiquibodies’ was introduced by our lab in 2014, and it 
and other ubiquibody-like technologies have since been engineered to 
create tunable silencing of specific protein targets.  
This work has shown ubiquibodies to be effective protein silencers. 
Ubiquibody-mediated silencing is postulated to be achieved by proteolytic 
cleavage of target proteins inside the proteasome. This generation of 
ubiquibodies relies on the simultaneous interaction of three independent 
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proteins, E2, ubiquibody, and target, where the ubiqiubody acts as 
scaffold bridge between the E2 and target proteins. (Figure 5.1).   
 
 
Figure 5.1: The anatomy of a ubiquibody. 
 
The three domains of the ubiquibody, DBP, linker, and catalytic 
domain, function independently and form a modular platform that is 
amenable to rapid exchange of domains. In this report, ubiquibody-
driven silencing has been found to be a function of several factors, 
including E2 specificity, catalytic effectivity and processivity, acceptor 
lysine selectivity, cognate target specificity and affinity, and poly-
ubiquitin linkage specificity.  
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Discussion 
The Designer binding protein 
All foreseeable generations of ubiquibodies will require directed-
target specificity. By genetically encoding this specificity in the form of a 
DBP, large portions of the proteome that were previously inaccessible 
become targetable. Many types of DBP have been shown to be amenable 
to the ubiquibody scaffold, such that the ubiquibody technology is likely 
never to limited for wont of a DBP. At most, additional library screening 
may be necessary to acquire the desired binder.  
One of the key considerations with DBP selection is its affinity for 
the cognate target. Affinities have played roles in PTM-specific silencing, 
as well as a possible cause of differential silencing by ubiquibodies 
specific for the same target. Natural PTM-specific silencing has been 
observed in several cases, including the MAPK pathway that was targeted 
by ubiquibodies here [88]. Further exploration into PTM-specific silencing 
will depend on both advancements to PTM binding capabilities (PTM-
specific antibodies or DBPs) and characterization of the natural 
mechanisms with which cells differentiate protein subpopulations. 
The E3 Catalytic domain 
The type of E3 catalytic domain has been a common factor between 
all experimental ubiquibodies reported here. As an enzymatic process 
that requires the assembly of multiple protein subunits, the optimizing 
the kinetics of the association and dissociation of each subunit will likely 
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be an important part of pushing the reaction towards the kinetically 
active complex, when irreversible covalently linkage of ubiquitin occurs 
(Figure 5.2). Furthermore, the ability to hack the ubiquitin code (Figure 
5.3) will depend on the E2/E3 interaction; the U-box offers advantage 
here, in that it naturally interacts with a large subset of E2s. Directed 
evolution of this domain could yield ubiquibodies capable of selectively 
interacting with E2s specific for different types of ubiquitin linkage.  
The incorporation of a HECT, or HECT-like, E3 catalytic domain 
would greatly reduce the complexity of this system, as complexes of only 
two enzymes would be required to assemble to mediate ubiquitin ligation. 
Smurf2 has been proposed as a potential donor of catalytic activity, and 
investigations into bacterial IpaH have already begun. As always, if 
biologists want to try it, nature has beaten them to it [25]. Bacterial E3 
ubiquitin ligases hijack mammalian degradation machinery to subvert 
host defense mechanisms and better effect their pathogenicity [89]; 
because bacteria evolved it first, many of these E3s come equipped with 
mechanisms which could become the focus of research into ‘deliverable’ 
ubiquibodies.  
Not all ubiquibody-like technologies will depend upon engineered 
E3 catalytic activity. Proteolysis targeting chimeras (PROTACs) are 
another technology that hijack the UPP, but instead of containing 
catalytic activity themselves, form a bridge between native E3s and target 
proteins [90]. Alternatively, in Clift et al. proposed a much larger 
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approach (measured in kDa), using full length-antibodies as the bridge 
substrates and an E3 ubiquitin ligase [91]. These two technologies 
demonstrate the extremes between which UPP-hijacking technologies can 
function.  
 
 
Figure 5.2: Kinetics of ubiquitination with dimeric ubiquibodies.  
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Figure 5.3: The ubiquitin code.  
Lysine 11 and lysine 48 poly-ubiquitin linkages target substrates to the proteasome, 
while lysing 63 linkages are purported to be involved lysosomal targeting by 
autophagy. [42] 
 
The Linker 
The small flexible linker was not originally considered an 
independent domain of the ubiquibody. Here, the linker has been shown 
to play an important role in determining the ubiquitination profile of 
target substrate lysines. With the growing number of advancements in 
linker biology, the domain will likely provide an important control point 
for the ubiquitination profile of the ubiquibody and enzymatic activity 
overall.  
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One of the key considerations for ubiquibody effectivity, 
superficially explored here, is expression of the fusion protein, either in 
bacterial or in mammalian cells. Depending upon the application, 
significant levels of protein will be required. While all CHIPΔTPR fusion 
proteins reported here, expressed exceptionally well in a bacterial 
expression strains (E. coli BL21(DE3)) from high-copy plasmids, they did 
not all express equally well in mammalian cells from mammalian 
expression vector pcDNA3. In preliminary experiments, uAbSmurf2 and 
uAbParkin constructs similarly suffered from undetectable expression in 
mammalian cells (data not shown). Also, while ectopic expression has 
been the method of introduction of ubiquibodies to mammalian cells, 
other means of delivery will need to be explored going forward.   
 
Conclusions 
The future of ubiquibody, despite its name, need not be limited to 
ubiquitination. Other catalytic domains, such as deubiquitinating 
enzyme (DUB) or sumoylation catalytic domains, could be incorporated 
into the existing scaffolds. Modularity will play an important role in all 
rationally designed synthetic enzymes, and the knowledge concerning 
one domain gleaned here may facilitate the hijacking of completely 
unrelated biological systems.  
Inducible enzymes have been designed for other applications. As 
they exist now, ubiquibodies are constitutively active in the presence of 
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their target and the UPP. Light or chemically activated domains could be 
added to the ubiquibody scaffold, allowing for temporal targeted protein 
silencing. Indeed, per the time of this report, the first steps into these 
uncharted realms of ubiquitination technology have already been taken 
by members of this lab.  
The final piece to solving the puzzle of targeted protein silencing 
will be the full elucidation of the ubiquitin code. Understanding the 
effects of different linkages, and, then, selectable formation of those 
linkages on target proteins will constitute an invaluable advancement in 
protein silencing. And, as ubiquitination is involved in so many cellular 
processes, ubiquibodies, though born from the need for protein-level 
silencing technologies, could yet transcend their intended purpose to, 
unimagined possibilities.  
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APPENDIX A 
SEQUENCES 
 
A.1. CHIPΔTPR 
 
-Linker-hCHIPΔTPR-SalI-Flag-His6 
 
GSGSGRLNFG DDIPSALRIA KKKRWNSIEE RRIHQESELH SYLSRLIAAE - 50 
RERELEECQR NHEGDEDDSH VRAQQACIEA KHDKYMADMD ELFSQVDEKR -100 
KKRDIPDYLC GKISFELMRE PCITPSGITY DRKDIEEHLQ RVGHFDPVTR -150 
SPLTQEQLIP NLAMKEVIDA FISENGWVED YVDGADYKDD DDKGHHHHHH -200 
 
A.2. scFv-C4 
 
 
 
A.3. Huntington N17 Peptide 
 
MATLEKLMKA FESLKSF    - 17 
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A.4. YS1 
 
MVSSVPTKLE VVAATPTSLL ISWDASYSSS VSYYRITYGE TGGNSPVQEF - 50 
TVPGSKSTAT ISGLKPGVDY TITVYAYSYY YYYYSSPISI NYRT       - 94 
 
A.5. OFF7 
 
DLGRKLLEAA RAGQDDEVRI LMANGADVNA ADNTGTTPLH LAAYSGHLEI - 50 
VEVLLKHGAD VDASDVFGYT PLHLAAYWGH LEIVEVLLKN GADVNAMDSD -100 
GMTPLHLAAK WGYLEIVEVL LKHGADVNAQ DKFGKTAFDI SIDNGNEDLA -150 
EILQKLNEF                                              -159 
 
A.6. ERK DARPins 
 
 
102 
 
A.7. human Smurf2 
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A.8. human Parkin 
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APPENDIX B 
E2 CONJUGATING ENZYMES 
 
B.1. E2 Enzymes Screened 
 
E2 Conjugating 
Enzyme1 
Alternate 
Name Tag 
Ube2A HR6A No tag 
Ube2B HR6B No tag 
Ube2C UbcH10 T7 
Ube2D1 UbcH5A T7 
Ube2D2 UbcH5B T7 
Ube2D3 UbcH5C No tag 
Ube2D4 UbcH5D T7 
Ube2E1 UbcH6 No tag 
Ube2E2 UbcH8 T7 
Ube2E3 UbcH9 No tag 
Ube2F NCE2 T7 
Ube2G1 Ubc7 T7 
Ube2G2 Ubc7 No tag 
Ube2H UbcH2 No tag 
Ube2I Ubc9 No tag 
6His-Ube2J1 NCUBE1 His-T7 
Ube2J2 NCUBE2 T7 
Ube2K Ubc1 No tag 
Ube2L3 UbcH7 No tag 
Ube2L6 UbcH8 No tag 
Ube2M Ubc12 No tag 
Ube2N Ubc13 No tag 
Ube2N/Ube2V1 Ubc13/Uev1A No tag/T7 
Ube2N/Ube2V2 Ubc13/Mms2 No tag/No tag 
6His-Ube2Q NICE-5 His-T7 
Ube2Q2 - No tag 
Ube2R1 CDC34 T7 
Ube2R2 CDC34B T7 
Ube2S E2-EPF T7 
Ube2T HSPC150 No tag 
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Ube2V1 Uev1A T7 
Ube2V2 Mms2 No tag 
6His-Ube2W Ubc16 His-T7 
6His-Ube2Z USE1 His-T7 
1E2s were obtained from Ubiquigent 
 
B.2. Human E2 Enzymes not covered 
AKTIP FLJ13258  
BIRC6 BRUCE  
UBE2E4P UbcM2  
UBE2L1 UBEL1, L-UBC, 
UBCH7N3 
 
UBE2L2   
UBE2L4   
UBE2L5   
UBE2NL   
UBE2U MGC35130  
2Full list of human E2 conjugating enzymes from [69] 
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